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Cystic fibrosis (CF), the most common lethal autosomal recessive disorder among 
Caucasians, affects approximately 30,000 individuals in the United States. CF is caused 
by loss of function mutations in the CF transmembrane conductance regulator (CFTR) 
gene. Once the disease-causing gene for CF was identified, numerous studies attempted 
to correlate CFTR mutations with specific CF phenotypes because genotype-phenotype 
correlations can predict a course of the disease and lead to the design of a genotype-
specific therapeutic strategy. Unfortunately, distilling correlation has been challenging 
for several reasons. First, CF is a multi-system disease that involves different organs and 
its phenotype is analyzed in context of its various clinical components. Second, patients 
exhibit a wide range of disease severity although CF is considered a classic Mendelian 
disorder. In fact, the degree of variability observed in 293 individuals with the identical 
CFTR mutations suggests that factors other than the CFTR genotype contribute to lung 
function variation. Given that obstructive lung disease is the cause of death in 90% of CF 
patients, there has been continued interest in determining these factors that influence the 
severity of pulmonary disease in CF patients. 
MC3R has been identified as a compelling candidate for modifying CF lung 
disease. Before exploring its role as a modifier, we aimed to understand the molecular 
organization of MC3R. Using 5’ RACE, we discovered a novel upstream exon that 
extends the length of the 5’ UTR in MC3R without changing the ORF. The full-length 5’ 
UTR directs utilization of an evolutionarily conserved second in-frame ATG as the 
primary translation start site. MC3R synthesized from the second ATG is localized to 
apical membranes of polarized Madin Darby Canine Kidney (MDCK) cells, consistent 
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with its function as a cell surface mediator of melanocortin signaling. Expression of 
MC3R causes re-localization of a known accessory factor for MC2R, MRAP2, to the 
apical membrane, which is coincident with the location of MC3R.  In contrast, protein 
synthesized from MC3R cDNAs lacking the 5’ UTR displayed diffuse cytosolic 
distribution and no effect upon the distribution of MRAP2. Our findings demonstrate that 
a previously unannotated 5’ exon directs translation of MC3R protein that localizes to 
apical membranes of polarized cells. 
To define the mechanism of lung disease in CF that underlies the linkage signal at 
chr20q13.2, we evaluated MC3R as a potential modifier of lung function. Three rare 
variants in MC3R were significantly associated with lung function in individuals with CF, 
suggesting  that variation in MC3R contibutes to CF lung disease severity. In silico 
prediction tools and in vitro studies were performed to understand the functional effect of 
the rare variants. We demonstrated that antagonist (siRNA) or agonist ([D-Trp
8
]-γ-MSH) 
of MC3R can modulate pro-inflammatory cytokine expression. Evidence for the presence 
of MC3R in primary airway epithelial cells of the lungs further supported our hypothesis 
that MC3R is a modifier of lung function in CF. These studies support the role of MC3R 
as a mediator of the inflammatory response and a potential therapeutic target in the 
treatment of CF. 
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 Cystic fibrosis (CF) is the one of the most common lethal autosomal recessive 
disorder among Caucasians. CF affects approximately 30,000 Americans with 1,000 new 
cases reported annually in the US (1). Individuals with CF have obstructive and 
inflammatory disease that affects the lungs, pancreas, sweat glands, intestines, biliary 
tract, and male reproductive tract (Figure 1.1) (2). Pulmonary disease accounts for most 
of the morbidity and mortality in patients with CF (3). With significant advances in the 
diagnosis and treatment of CF, patients are experiencing better overall lung function and 
the median predicted age of survival has steadily risen from 28 years in 1988 to 41 years 
in 2012 (4). 
 CF is caused by loss of function mutations in the CF transmembrane conductance 
regulator (CFTR) gene (5). CFTR encodes a cAMP-regulated chloride channel that is 
expressed on the apical membrane of epithelial cells (6). The role of CFTR in epithelial 
cells extends beyond chloride permeability as it is known also to regulate transepithelial 
sodium channels (7), potassium channels (8), and bicarbonate transporters (9,10). Loss of 
chloride transport in pulmonary epithelium leads to an increase in intracellular salt 
concentration (11). This salt imbalance dehydrates the lumen, which impairs ciliary 
function. Abnormalities in submucosal gland fluid secretion affect the composition and 
quality of airway mucus, making easier for bacteria to be trapped (12). Defective 
bacterial clearance leads to chronic infection and persistent  inflammation (13). 
One of the hallmarks of CF is allelic heterogeneity. To date, there have been close 
to 2000 mutations found in CFTR. Some of the phenotypic variability in individuals with 
CF can be explained by the nature of the mutations in CFTR. However, genotype-  
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Figure 1.1: CF is a highly variable, multi-system disease caused by mutations in 
CFTR. The consequences of CF manifest in multiple organs, including the lungs, 














phenotype studies have revealed that variability in disease severity is influenced by 
factors other than the CFTR genotype (14-16). This chapter will discuss the clinical 
manifestations of CF, the classes of CFTR mutations, the correlations between genotype 
and phenotype, the environmental and genetic modifiers, and the role of melanocortin-3-
receptor (MC3R) as a potential modifier of lung disease severity in CF.  
 
Clinical Background 
Obstructive lung disease is the cause of death in 90% of CF patients (17). 
However, patients exhibit a wide range of phenotypic presentations and severity. The 
classic form of CF is diagnosed if a patient has elevated sweat chloride and demonstrates 
clinical disease in one or more organs as described below (2).  
 
Lung 
 The loss of CFTR chloride channels produces an abnormally high salt 
concentration in the airway surface fluid (18). Impaired transport of chloride and sodium 
across the respiratory epithelium impairs mucociliary clearance and causes a recurrent 
cough that becomes persistent. The chronic airway obstruction is followed by 
colonization with P. aeruginosa and S. aureus (19). Because these pathogens become 
well established within the airway surface, they are not effectively eradicated. 
 In addition to pulmonary obstruction, inflammation contributes to the decline in 
respiratory function in CF. Chronic bacterial infection in the airways results in 
inflammation and leads to progressive lung tissue damage. Elevated levels of pro-
inflammatory cytokines, such as interleukin (IL)-8, and reduced levels of anti-
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inflammatory cytokines have been found in the airways of patients with CF (20-22). Toll-
like receptors are known to mediate inflammation in part by activation of the 
transcription factor NF-κB, which induces the production of inflammatory proteins and 
cytokines (23). Different therapies, such as antibiotics (24-26), hypertonic saline (27), 
and bronchodilators (28-30), have been found to slow the progressive respiratory failure. 
These therapies have been responsible for improvement in patient survival (31-33).  
 
Pancreas 
 CF is associated with three different types of pancreatic disease: pancreatic 
insufficiency, pancreatitis, and CF-related diabetes (CFRD).  
Pancreatic insufficiency (PI) is defined by abnormal exocrine function, and it 
occurs in over 80% of patients with CF. The damage begins in utero and can be identified 
in neonates on the basis of elevated serum immunoreactive trypsinogen (IRT). Hence, 
IRT serves as a marker for newborn screening for CF (34). While the CFTR genotype 
does not predict survival due to the complex interaction between genetic and 
environmental modifiers of lung disease, it is highly predictive of pancreatic exocrine 
status (35).   
The defective chloride secretion in the pancreas causes progressive pancreatic 
damage, leading to pancreatitis. Pancreatitis occurs mainly during adolescence and young 
adulthood. While pancreatitis is reported for patients carrying a wide range of mutations, 
the incidence of pancreatitis is higher among patients with pancreatic sufficiency (PS) 
than those with PI (36).  
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Patients with exocrine pancreatic insufficiency often develop endocrine pancreatic 
dysfunction, which ultimately results in CFRD.  CFRD illustrates features of both type I 
and type II diabetes, including decreased insulin production and insulin resistance (37). 
Approximately 25% of CF patients develop CFRD by 20 years of age, and the risk 
depends on the CFTR genotype (38). Several studies have shown that pulmonary function 
is worse in CF patients with CFRD compared with those without diabetes (39-41).  
 
Intestine 
 Up to 20% of patients with CF are born with intestinal obstruction called 
meconium ileus (MI) (42). MI occurs in the distal ileum or proximal colon and is fatal 
unless surgically treated to relieve the obstruction (43). The pathogenesis of MI is 
unclear, but it is believed to result from the loss of CFTR-mediated chloride and/or 
bicarbonate transport by the intestinal epithelium (44,45). Nutritional evaluation of 
infants and children revealed an association of MI with malnutrition in CF, potentially 
due to the surgical treatment for MI and poor essential fatty acid status (46). It has been 
demonstrated that in a pig model of CF, intestinal expression of CFTR without pancreatic 
or hepatic correction can partially restore CFTR-mediated anion transport and rescue MI 
(47). The optimal medical treatment and nutritional intervention for CF patients with MI 
need to be further investigated. 
 
Male reproductive tract 
 More than 98% of men with CF are infertile due to congenital bilateral absence of 
the vas deferens (CBAVD) (2). These men are able to produce sperm, but they lack the 
canal that carries sperm from the testis to the ejaculatory duct. In a guideline for the 
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appropriate use of genetic tests in infertile couples, screening for CFTR mutations 
including the 5T allele is strongly recommended with a diagnosis of CBAVD (48). It is 
important to note that some individuals with the 5T allele in trans with a severe CFTR 
mutation may have nonclassic CF or male infertility due to CBAVD; in 40% of the cases, 
they are healthy and fertile as a consequence of incomplete penetrance of the 5T variant 
(49,50). It has been recently demonstrated that the number of TG repeats adjacent to 5T 
determines disease penetrance (51). Hence, diagnosis and interpretation in the case of the 
5T variant in intron 8 of the CFTR gene should be done in conjunction with TG repeating 
testing. 
 
CFTR Mutation Class 
The CFTR gene is located on chromosome 7q31.2 and encodes a 6.5 kb mRNA 
transcript with 27 exons. The CFTR protein is comprised of 1480 amino acids and 
contains two six-pass transmembrane domains, two nucleotide binding domains and a 
regulatory domain. CFTR is synthesized in the ER and N-linked glycosylated at amino 
acid residues 894 and 900 (52). The mature CFTR protein is then transported to the cell 
membrane under the guidance of cargo proteins, such as synthaxin 1A and SNAP-23, that 
bind to the N-terminus, as well as NHERF, CAL, and synthaxin 6 that bind to the C-
terminal tail of CFTR (53-56). The fully glycosylated wildtype CFTR is located at the 
plasma membrane (57) and is detected as ‘C band’ at 170 kD. The mutant CFTR, such as 
F508del, is detected as ‘B band’ at 140 kD because it is not fully processed (58). As a 
result, it is retained in the ER and subsequently degraded by a proteasome. 
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Close to 2000 variants in CFTR have been described to date, but one mutation – 
F508del – accounts for approximately 70% of CF chromosomes (59). Most of the CFTR 
mutations are extremely rare. Only six other mutations have a pan-ethnic frequency of 
greater than 1%: G542X, W1282X, G551D, 621+1G>T, N1303K, and R553X (60). The 
CFTR mutations can be classified according to the mechanisms by which mutations 
disrupt CFTR protein synthesis and its chloride channel function (Figure 1.2) (61,62). 
This classification, however, is deemed simplistic because mutations can affect multiple 
properties of CFTR, such as protein folding and gating function. The understanding of 
the molecular mechanism of each CFTR dysfunction allows mutation-specific 
pharmacotherapy to be developed (63).   
 
Class I 
Class I mutations lead to the creation of unstable, truncated mRNA transcript as a 
result of abnormal splicing or insertion of a premature stop codon. G542X is an example 
of a nonsense mutation in this class that significantly reduces the level of mutant CFTR 
compared to wildtype CFTR. There is evidence that null mutations can be overcome by 
aminoglycoside antibiotics, which suppress premature stop codons and permit translation 
to continue to synthesize full-length CFTR (64,65).  
 
Class II 
Class II mutations produce a misfolded protein that lacks a mature glycosylation 
pattern. As a result, the protein is retained and degraded in the ER by the quality control 
mechanisms. The most common mutation in CFTR, F508del, belongs to this category.  
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Figure 1.2: CF is characterized by extensive allelic heterogeneity. CF mutations can 
be grouped into several categories or types based on how the mutations affect the CFTR 
protein. About half of the individuals with CF are homozygous for the most common 
CFTR mutation, F508del, which causes defective protein folding and processing in the 
ER, resulting in minimal amounts of CFTR at the cell surface. Several corrective agents 
are approaching clinical trials. Kalydeco
TM
 is the first and only FDA-approved drug to 
treat individuals with the G551D mutation. (Figure from Herrmann et al. Best Pract Res 









Class II mutations result in a severe clinical phenotype as CFTR is virtually absent at the 
cell surface. It has been demonstrated that class II mutants, while misfolded, can conduct 
some chloride conductance (66,67). This reveals future opportunity to design therapies 
that can help mutant proteins escape ER-associated degradation and permit surface 
expression of the partially functioning chloride channel.  
 
Class III 
Class III mutations disrupt the activation and regulation of CFTR at the cell 
membrane. For instance, G551D is expressed at the cell surface but is unable to conduct 
chloride in response to elevated cAMP due to impaired ATP binding. In Jan. 2012, a drug 
called Ivacaftor (Kalydeco
TM
) was approved by FDA for CF patients who have at least 
one copy of the G551D mutation (68). The effectiveness of Kalydeco
TM
 to increase the 
activity of defective CFTR protein represents a significant milestone in the development 
of treatments for CF. 
 
Class IV 
 Class IV mutations give rise to functional proteins that localize to the apical 
surface but have reduced chloride conductance. One way to overcome this problem is by 
increasing the overall cell surface content of these mutant proteins to compensate for the 
relative reduction in conductance. CF patients with one or two copies of class IV 
mutations, such as R117H, usually have a milder CF phenotype (69). F508del is also a 





 Class V mutations, such as 3849+10kb C>T, generate properly and improperly 
spliced transcripts. These patients often demonstrate milder manifestation of the disease 
since their CFTR protein is active but reduced in number. The variable disease expression 
has been shown to have inverse correlation with the level of correctly spliced transcripts 




Once the disease-causing gene for CF was identified, numerous studies attempted 
to correlate CFTR mutations with specific CF phenotypes. Genotype-phenotype 
correlations can predict a course of the disease and lead to the design of a therapeutic 
strategy based on the specific genotype (72). Unfortunately, distilling correlation has 
been challenging for several reasons. First, CF is a multi-system disease that involves 
different organs and its phenotype is analyzed in context of its various clinical 
components, such as pancreatic exocrine function, pulmonary disease, sweat chloride 
level, vas deferens abnormalities in males (73). Second, patients exhibit a wide range of 
disease severity although CF is considered a classic Mendelian disorder. It is perhaps not 
surprising given the number of CFTR mutations that have been identified so far. Lastly, 
most CFTR mutations are extremely rare. Determining the functional consequence of 
each mutation is essential in assessing its disease liability, but it is infeasible to perform 
analysis of every mutation. Grouping mutations according to the mechanisms by which 
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mutations disrupt CFTR protein synthesis has improved our ability to uncover which 
specific phenotypes are strongly correlated with particular classes of mutations.  
The highest degree of correlation between the CFTR genotype and the CF 
phenotype is found in the pancreatic status. Concordance of pancreatic function status 
among affected individuals within the same family suggested that genetic factors, such as 
the CFTR genotype, affects the degree of pancreatic disease (74). We now know that 
CFTR genotype is a predictor of pancreatic status because previous studies have 
demonstrated that patients with PS carry mutations (classes IV-V) that are different from 
those with PI (classes I-III) (73,75). In light of this observation, mutations that are 
definitively associated with PI are often categorized as severe mutations. In contrast, 
mutations that are associated with PS are labeled as mild mutations. Identification of 
patients carrying two severe alleles predictive of PI through newborn screening program 
allows early nutritional support and pancreatic enzyme supplements (76).  
Unlike the strong association between the CFTR genotype and the pancreatic 
phenotype, the severity and course of pulmonary disease are not predicted by the 
genotype. One study has posited that the presence of class I or II mutations on both 
chromosomes is associated with worse respiratory disease and a lower probability of 
survival (77). Nonetheless, it is generally agreed that correlation between severity of 
pulmonary disease and genotype is difficult to discern (73,78). In a study of 293 patients 
homozygous for F508del mutation, considerable variability in pulmonary function was 
found at all ages (Figure 1.3) (74). The degree of variability observed in individuals with 




Figure 1.3: The variability in lung function with an identical CFTR genotype is 
considerable. The airway flow measure, forced expiratory volume in one second (FEV1), 
is plotted against age in individual patients who are homozygous for F508del mutation. 
The red and blue circles represent 17-year-old patients with 10% and 90% FEV1 
measures, respectively. The variability in pulmonary function indicates that there must be 
factors other than the CFTR genotype that affect the severity of lung disease. (Figure 








function variation, thus emphasizing the importance of determining these factors that 
influence the severity of pulmonary disease in each patient (79,80).  
 
Modifiers of CF Phenotype 
Environmental modifiers 
Phenotypic variation in a monogenic disorder, such as CF, can be attributed to 
several sources, including different mutations in the disease-causing gene, genetic 
modifiers, environmental factors, random events, and interactions between any of these 
factors (Figure 1.4) (81). Since environmental factors account for 50% of the variation in 
CF lung function (82), identifying these factors can help in development of therapies and 
interventions to decrease the morbidity and mortality associated with the disease. So far, 
the following environmental and socioeconomic factors have shown to impact lung 
function in CF: secondhand smoke (83), health insurance (84), household income (85), 
air pollution (86), ambient temperature (87), and environmental allergens (88). Three 
factors listed above will be described in detail. 
Secondhand smoke causes premature death and disease in non-smoking children 
and adults (89). Exposure to secondhand smoke has immediate adverse effects on the 
cardiovascular system and increases the risk for acute respiratory infections. Perhaps not 
surprisingly, any exposure to secondhand smoke has been shown to adversely affect 
cross-sectional as well as longitudinal measures of lung function in those with CF (90-
92). 
A growing body of evidence indicates that socioeconomic status (SES) is a strong 
predictor of health status in several chronic diseases. Improved health is associated with  
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Figure 1.4: Multiple factors interact to determine the CF phenotype. Phenotypic 
variation seen in individuals with CF can be attributed to several factors, such as the 
CFTR genotype, modifier genes, environmental factors and stochastic events. (Figure 















higher income, more education, better job and safer neighborhood. Using public 
assistance as a proxy for low SES, it has been demonstrated that Medicaid patients with 
CF have poorer lung function and require more treatments for pulmonary exacerbations 
than non-Medicaid patients (93). This difference may be explained by inadequate access 
to primary care or poor adherence to prescribed regimens. Interestingly, no significant 
relationship was found between SES and CF-related morbidity in the Canadian 
population (94). The authors speculate that universal access to health services in Canada 
that covers the cost of most CF medications and nutritional supplements may ameliorate 
previously documented SES disparities.  
Lastly, the presence of environmental allergens has been associated with poorer 
respiratory outcomes in other obstructive lung diseases, such as asthma (95) and COPD 
(96). Similarly, environmental allergens were found to be associated with more rapid 
decline in lung function in CF (88). This suggests that management of environmental 
allergies can be a target for therapeutic interventions for individuals with CF. 
 In contrast to the environmental modifiers that have adverse effects on CF 
phenotype, there are therapeutic treatments that improve the quality of life of CF patients. 
Improved growth and nutritional status early in life has been associated with better 
pulmonary function later in life, which suggests that early intervention, such as 
nutritional counseling, can have a favorable impact on survival by slowing the rate of 
decline in pulmonary function (97-99). Pancreatic enzyme supplementation also has a 
significant impact on survival of CF patients (100). Since most patients have abnormal 
pancreatic exocrine function, pancreatic enzyme replacement therapy is utilized by about 
90% of CF patients in Northern Europe where F508del mutation is commonly found 
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within the CF population (101). Lastly, the wide use of antibiotics for lung infections has 
contributed to improvement in survival (102). The long-term use of low dose 
azithromycin was demonstrated to significantly reduce the number of pulmonary 
exacerbations that required additional courses of antibiotics prior to infection with P. 
aeruginosa (103). Similarly, the administration of inhaled tobramycin in conjunction with 
standard therapy for CF improved lung function, decreased bacterial load in sputum, and 
reduced the need fewer hospitalizations (24).  
 
Genetic modifiers 
Family-based studies have been used to estimate genetic and nongenetic 
contributions to disease severity in CF. The role of genetic modifiers was affirmed when 
pulmonary function was found to be more similar among monozygotic twins than 
dizygotic twins and sibling pairs (82). Furthermore, heritability of lung function severity 
has been estimated to be 0.54-1 using cross-sectional and longitudinal measures of lung 
function in affected twins and siblings (104). The higher concordance of lung function in 
monozygotic twin pairs and the high estimate of heritability for the FEV1 measures in 
affected siblings validate the importance of searching for CF modifier genes. 
Identification of the modifier genes will help us understand the pathogenesis of CF and 
lead to a more rational use of conventional treatments. A number of candidate genes have 
been studied in two or more separate populations of individuals with CF. Three modifier 




Genetic variation in TGFβ1 (transforming growth factor β1) gene as well as the 
upstream region has been found to modify lung disease severity in CF. TGFβ1 is a 
cytokine that plays an important role in regulating the immune system. Dysfunction in 
TGFβ1 signaling has been associated with numerous diseases, such as Alzheimer’s 
disease (109), inflammatory bowel disease (110) and congenital heart disease (111). 
Using family-based transmission analysis, polymorphisms in TGFβ1 was found to 
modify CF lung function, but not nutritional status. Interestingly, non-F508del 
homozygous patients carrying at least one C-T-C haplotype had better lung function than 
patients carrying the T-C-C haplotype, suggesting that association of TGFβ1 alleles with 
lung function variation was dependent upon CFTR genotype (106). 
Polymorphisms in IFRD1 (interferon-related developmental regulator 1), histone-
deacetylase-dependent transcriptional co-regulator that is expressed during terminal 
neutrophil differentiation, have been shown to contribute to lung function variation in CF 
independent of CFTR genotype. In particular, the rs7817 polymorphism is significantly 
associated with cross-sectional and longitudinal measures of lung function. The follow-
up analysis confirmed that the heterozygote genotype (CT) of IFRD1 is associated with 
poorer lung function than either homozygote (CC or TT). Functional studies using Ifrd
-/-
 
mice showed delayed bacterial clearance but ameliorated disease with less weight loss 
and less neutrophilic inflammation upon challenging the mice with P. aeruginosa. 
Analysis of human neutrophils showed a significant association with IFRD1 
polymorphisms with neutrophil effector function. Though neutrophils are not the only 
CF-relevant cells influenced by IFRD1 polymorphisms, these data suggest that IFRD1 
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affects the pathogenesis of CF lung disease through the modulation of neutrophil effector 
activity. 
Variations in MSRA (methionine sulfoxide reductase A) gene are associated with 
MI, the intestinal obstruction phenotype of CF. MI, like lung disease severity, is a highly 
heritable trait, further supporting that genetic modifiers are probably responsible for this 
manifestation. Functional studies using two CF mouse models – null model with high 
rates of obstruction and p.Arg117His model with lower rates of obstruction – revealed 
that loss of Msra provides protection from intestinal obstruction during the time of 
weaning. Like IFRD1, MSRA modifies MI independently of variation in CFTR. 
Discovery of MSRA as a modifier of MI offers new insight into the mechanism of 
intestinal complication of CF. 
 
Twin-Sib Study for Investigation of CF Lung Disease Severity  
 In addition to TGFβ1 and IFRD1, genome-wide association and linkage studies 
identified modifier loci of lung disease severity in CF at 11p13 and 20q13.2 (112). FEV1, 
the most useful measure of lung disease severity and a well-established predictor of 
survival (113), was used in this study to compare lung function measures. This thesis will 
focus on 20q13.2, the locus of interest that contains a potential modifier gene, MC3R. 
 Non-parametric linkage analysis of 486 sibling pairs from the family-based study 
discovered a genome-wide significant locus (LOD = 5.03) on 20q13.2 (Figure 1.5). This 
locus is responsible for as much as 50% of the variation in lung function in the sibling 
pairs with CF. This result was followed by SNP association testing in the linked region 
using unrelated individuals with two severe CFTR alleles from other studies. In this 1.3  
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Figure 1.5: 20q13 contains a modifier for lung disease severity in CF. Genome-wide 
linkage scan for the lung phenotype of 486 sibling pairs with CF identified a locus on 
chromosome 20q13 that contains a modifier for lung function. There are five genes found 
in the 1.3 Mb region of maximum linkage, one of which is MC3R. The bottom figure 
shows the LocusZoom plot of association in the critical linkage region. (Figures from 









Mb linked region, demarcated by 1 LOD unit below the maximum, there were two 
clusters of SNPs. A 16-kb cluster of SNPs in high LD within the 1 LOD support interval 
was located is a gene desert and are centromeric to five genes: CBLN4, MC3R, AURKA, 
CSTF1 and CASS4. One SNP within this cluster (rs6024460; LOD = 3.87) exceeded the 
threshold for regional significance. Notably, a second smaller cluster of SNPs covering 
approximately 8 kb was identified near MC3R. The SNP with the highest LOD score in 
the second cluster (rs1326022; LOD = 2.94) was located 20 kb downstream of MC3R, 
raising the possibility that common variants in or near this gene may influence lung 
function.  
 
MC3R as a Potential Modifier of Lung Function in CF 
 None of the SNPs in the 16-kb cluster lies within a gene, but this does not exclude 
the possibility that this region regulates expression of the downstream genes. However, 
the second smaller cluster of SNPs is directly over MC3R, a promising candidate gene for 
modifying lung function in CF (114). Various mechanisms by which MC3R affects CF 
lung disease are explored here. 
There are several reasons why MC3R is a biologically plausible candidate for 
modifying CF lung disease. First, MC3R and the family of melanocortin receptors have 
known roles in inflammation in the brain and outside of central nervous system (115-
117). Individuals with CF have an increased level of NF-κB-regulated proinflammatory 
cytokines, such as IL-8 (118,119). Since inflammation is a key feature of CF lung 
disease, altering the heightened baseline level of inflammation or modulating repetitive 
cycles of inflammation due to infection could reduce lung injury in CF patients (120). 
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Along these lines, Getting et al. reported that melanocortin peptides inhibit leukocyte 
accumulation in allergic and non-allergic mouse models of lung inflammation (115). It 
has been demonstrated that binding of melanocortin to melanocortin receptors leads to an 
inhibition of the NF-κB signaling in macrophages as well as other inflammatory cells 
(121), and the same mechanism has been shown to be operant for MC3R in bronchial 
airway epithelial cells (116). Investigation of MC3R’s effect on the NF-κB signaling and 
the inflammatory response could lead to therapeutic interventions for modulating lung 
inflammation.  
Alternatively, MC3R may be involved in regulation of lung function by 
influencing energy homeostasis. Nutritional status has a significant impact on lung 
disease in CF patients (122). In the general population, both common and rare variants in 
MC3R are associated with weight gain in children (123-125). Furthermore, Mc3r
-/-
 mice 
have increased fat mass, reduced lean mass and higher feed efficiency compared to the 
wildtype littermates while eating less and maintaining normal metabolic rates (126). 
Since elevated resting energy expenditure is highly correlated with lung tissue damage in 
people with CF, prevention of negative energy balance could reduce pulmonary 
exacerbations (127). MC3R might contribute to the complex interaction between lung 
inflammation and malnutrition. 
Lastly, MC3R may directly influence CFTR expression. The idea that MC3R may 
increase the functional activity and cell surface expression of CFTR was derived from the 
result from an empiric screen where siRNAs targeting MC2R and MC3R partially 
restored CFTR function (128). This result was described in a patent filed by a Belgium 
company, Galapagos, in which they explained a method for identifying compounds that 
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increase the functional activity and cell surface expression of CFTR. The patent revealed 
that reduction of certain target genes, including MC2R, lead to proper post-translational 
modification of CFTR. CFTR correction was shown by a shift from B-band, representing 
the immature CFTR protein, to C-band, representing mature form of CFTR. The 
company validated this finding by correcting trans-epithelial chloride transport in primary 
bronchial epithelial cell cultures derived from a CF patient homozygous for F508del 
mutation (CFBE41o- cells). Table 1.1 includes the final list of 19 genes that show 
expression of increased cell surface expression of F508del CFTR upon reduction of a 
target mediated by at least two shRNAs. Interestingly, MC3R was on the preliminary list 
of 315 hits that restored CFTR-dependent halide flux activity but failed to be on the final 
list of hits because its effect was not recapitulated with a completely independent shRNA 
targeting MC3R through a difference sequence (David Fischer, personal communication, 
2010). Since MC3R and MC2R are in the same receptor family and they have high 
sequence homology, MC3R is a reasonable candidate for examination of its role in 
regulation of CFTR function. 
 
Melanocortin Receptor Family 
Overview 
MC3R is a G-protein-coupled receptor (GPCR) for melanocyte-stimulating 
hormone (MSH) (Figure 1.6). It belongs to the melanocortin family that consists of five 
GPCRs, which mediate key physiological functions, such as pigmentation, 
steroidogenesis, energy balance, and food intake (Table 1.2) (129). They are labeled 
MC1R to MC5R according to the order in which each was identified (130). To date, 
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Table 1.1: Efficacy of the restoration of chloride transport in primary CF bronchial 
epithelial cell culture. Whereas the baseline chloride flux in the CF culture is usually 
less than 2% of non-CF control culture, reduction of each target in this table, including 











Figure 1.6: Schematic presentation of the general structure of GPCR. MC3R is a 
GPCR that contains an extracellular N-terminus, followed by seven transmembrane 
















Table 1.2: Biological distributions and functions of melanocortin receptor family. 
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MC2R is the only member of this family that has known accessory factors: melanocortin-
2-receptor accessory protein (MRAP) and its paralogue MRAP2 (129,131). Inactivating 
mutations of MC2R and MRAP cause of familial glucocorticoid deficiency type 1 and 2, 
respectively (131). Mutations in MC4R are associated with 1-5% of early-onset human 
obesity (132).  
  
Mechanism of Action 
 Binding of melanocortin peptides to the melanocortin receptors stimulates 
adenylyl cyclase, elevates cAMP and leads to activation of PKA (133,134) . Interestingly, 
melanocortin peptides have been shown to mediate anti-inflammatory effects (121). 
Understanding the mechanism of action of melanocortin receptors is crucial in designing 
synthetic melanocortin agonist for appropriate receptors. The anti-inflammatory signaling 
pathway of melanocortin receptors will be described here. 
The melanocortin peptides have been reported to interact with cells of the immune 
system and down-regulate the production of pro-inflammatory cytokines (135,136). It is 
believed that melanocortins regulate inflammation by inhibiting activation of the 
transcription factor NF- κB (137-140). MC3R is the only melanocortin receptor that is 
specifically activated by γ-MSH (141). NF-κB induces transcription of many molecules 
involved in inflammation, including cytokines. When bound to IκB inhibitory proteins, 
NF-κB is retained in an inactive form in the cytoplasm. Once IκB is phosphorylated and 
subsequently ubiquitinated, NF-κB dissociates from its inhibitory proteins and 
translocates to the nucleus where it induces the transcription of inflammatory response 
genes (Figure 1.7). It has been demonstrated in several cell types that α-MSH prevents 
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Figure 1.7: Anti-inflammatory effects of melanocortins. The activation of 
melanocortin receptors prevents NF-κB translocation to the nucleus and inhibits 







NF-κB translocation upon being induced by inflammatory stimuli. NF-κB inhibition 
results from cAMP generation by α-MSH, activation of PKA, and prevention of IκB from 
phosphorylation (142,143). Hence, the melanocortins provide important targets for 
developing pharmacological agents that can potentially be used to modulate the 
inflammatory process (144). 
 
Localization of MC3R 
As a member of a family of proteins that signal through the GPCR pathway, 
MC3R should be translocated across the ER and localized at the cell surface to enable 
binding to its ligands. Several studies have investigated the localization of MC3R in 
different cell types (Table 1.3) (123,145,146). For example, one study indicated that HA-
MC3R, a fusion protein made from a commercially available plasmid that is forced to 
initiate MC3R synthesis at the first in-frame ATG, shows cell surface as well as 
intracellular expression in HEK293 cells (145). In contrast, other studies concluded that 
MC3R-EGFP and GFP-MC3R are expressed at the plasma membrane of HEK293 and 
COS-7 cells, respectively. In each case, intracellular expression is evident in the provided 
photomicrographs (123,146). One of the limitations of the previous studies is that the 
expression was only studied in non-polarized cells. Such cell types do not represent the 
true physiological state of MC3R because it is known to be predominantly expressed in 
the brain where polarized neurons have a distinct distribution of membrane proteins 
(147). CF is caused by dysfunction of CFTR in polarized airway epithelial cells of the 




Table 1.3: Localization of MCR expression by confocal microscopy. 
 MC3R (example 1) MC3R (example 2) MC3R (example 3) 






Cell  HEK293  COS-7  HEK293  
Fluorescence  Green – anti-HA  Green – GFP 
Red – nucleus  
Green – GFP  
Conclusion  WT MC3R was 
expressed on the cell 
surface as well as 
intracellularly (145)  
White arrows indicate 
the presence of 
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critical to their ability to maintain airway surface liquid (148,149). Thus, our interest in 
MC3R as a genetic modifier of lung function in CF requires investigation of its 
expression in the lung and localization in polarized cells.  
 
Interaction between the accessory proteins and melanocortin receptors 
 MRAP and MRAP2 are hypothesized to have other functions in addition to being 
accessory proteins for MC2R (150). Investigation of such roles of MRAPs can reveal 
their interactions with other melanocortin receptors and elucidate various mechanisms 
that control biologically relevant processes (Figure 1.8). All melanocortin receptors, 
including MC3R, have been demonstrated to functionally interact with MRAP and 
MRAP2 (131). In one study, MRAP enhanced MC3R coupling to adenylyl cyclase in 
response to stimulation with α-MSH in HEK293 cells (151). MRAP was shown to 
colocalize with MC3R in the perinuclear region, cytoplasm and plasma membrane (151). 
Colocalization of MRAP and MC3R indicates that these proteins may interact with each 
other and are trafficked to the cell membrane together. Further studies are needed to 
determine if and how MRAP stabilizes MC3R at the cell surface to decrease receptor 
degradation and increase receptor recycling. These effects of MRAP suggest that MRAP 
could be an integral modulator of MC3R. 
 
Present studies of MC3R as a modifier of lung disease in CF  
The work presented here represents an on-going study that will attempt to 
elucidate the mechanism of CF lung disease reflected by the linkage signal at chr20q13.2. 




Figure 1.8: Effect of MRAP on MC2R and MC3R in a signaling pathway. MC2R is 
retained in the ER in the absence of MRAP. MRAP assists MC2R trafficking to the cell 
surface and enhances MC2R signaling in the adrenal gland. MRAP has been found to 












modifying CF lung disease. Given that MC3R is known to be involved in lung 
inflammation and contributes to energy homeostasis, we selected MC3R as the most 
compelling candidate under the linkage peak. Ultimately, our goal is to provide insight 
from this research in the development of new therapies that will alleviate the longitudinal 
decline in lung function of CF patients.  
 Chapter 2 describes the molecular and cellular characterization of the human 
MC3R gene. Previously, MC3R was predicted to be a single-exon gene with unknown 
translation start site. My study revealed that MC3R contains an upstream exon that 
extends the length of 5’ untranslated region (UTR). The presence of 5’ UTR was 
necessary for initiation of translation from the second in-frame ATG. I also explored 
localization of full-length (exons 1 and 2) as well as partial (truncated exon 2) MC3R in 
polarized MDCK cells. Furthermore, I investigated the interaction between MC3R and 
MRAPs to determine how MC3R may be modulated. 
 In Chapter 3, I present data that supports MC3R as a potential modifier of CF lung 
disease. My work identified three rare coding variants in MC3R that associate with lung 
disease severity. I further expanded the role of MC3R as a lung modifier by examining 
how modulation of MC3R alters pro-inflammatory signaling. In addition, I inspected the 
expression of MC3R in primary airway epithelial cells of the lungs to support my 
hypothesis that MC3R modifies lung function in CF.  
 Taken together, this body of work suggests that MC3R acts as a modifier of CF 
lung disease by modulating inflammatory pathways in the airways. The work presented 
in this thesis can be utilized in designing new targets for therapies against pulmonary 





























The melanocortin receptor family, consisting of five G-protein coupled receptors 
(GPCRs), mediate key physiological functions such as pigmentation, steroidogenesis, 
energy balance, and food intake (129). Variation in the coding regions of melanocortin 
receptors has been associated with a number of medically important diseases and traits. 
For example, inactivating mutations of the melanocortin-2-receptor (MC2R) or MC2R-
accessory-protein (MRAP) are known to cause familial glucocorticoid deficiency 
(131,152), and mutations in MC4R are responsible for 1-5% of early-onset human obesity 
(132,153-157). Like MC4R, MC3R has been found to play a role in energy metabolism. 
Both common and rare variants in MC3R have demonstrated association with obesity, but 
results have been inconsistent (123,125,158-162). MC3R has also been associated with 
hypertension, tuberculosis susceptibility and inflammation phenotypes (115,163-165). 
We are interested in studying MC3R as a potential modifier of lung disease in cystic 
fibrosis (CF) (112). Before exploring its role as a modifier, we aimed to understand the 
molecular organization of MC3R by obtaining the full-length mRNA transcript, 
determining the native protein length, and verifying its cellular distribution. 
The NCBI Reference Sequence Database predicts MC3R to be a single exon gene 
and it is unclear if translation begins at the first or second in-frame ATG. While the 
second ATG is conserved across vertebrates, the first ATG is only conserved in non-
human primates (www.genome.ucsc.edu). Prior studies indicate that both ATGs can 
function as translation initiation codons and that the sequence between the first and 
second ATG is not critical for the ligand binding of the receptor (166,167). Recently, it 
has been shown that the second ATG is preferentially used as the translation initiation 
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site in a truncated form of MC3R (168). Lack of information regarding the composition 
of the full-length mRNA transcript as well as conflicting results on translation initiation 
prompted us to identify native transcription and translation start sites to gain a more 
complete understanding of the MC3R protein. 
Characterizing the localization of MC3R in a proper cell type is vital in 
deciphering its role in regulation of energy homeostasis in the general population and in 
modulation of lung function in tuberculosis and CF. As a member of a family of proteins 
that signal through the GPCR pathway, MC3R should be localized to the plasma 
membrane to enable binding to its ligands. Several studies have reported cytoplasmic and 
membrane localization of MC3R in different cell types (123,145,146). One of the 
limitations of prior studies is that localization was assessed in non-polarized cells. Such 
cell types do not represent the true physiological state of MC3R because it is known to be 
expressed in tissues, such as the brain, where polarized neurons have a distinct 
distribution of membrane proteins (147). Furthermore, as we investigate the role of 
MC3R as a genetic modifier of lung function in CF, we are interested in studying its 
localization in polarized cells derived from airway epithelia of the lungs. Finally, all 
melanocortin receptors, including MC3R, demonstrate functional interaction with 
accessory proteins MRAP and its paralogue MRAP2 (131). In this study, we provide 
evidence that MC3R and MRAP2 interact and colocalize in polarized MDCK cells. 
Molecular characterization of MC3R provides information essential to resolving its role 






The human MC3R gene has two exons.   
The NCBI Reference Sequence Database predicts MC3R to be a single exon gene 
and its transcript as intronless (NM_019888). The reference sequence of MC3R places 
the first in-frame ATG at base pairs (bp) 2 to 4, while the second and the third in-frame 
ATGs are located 37 and 109 codons downstream, respectively (Fig. 2.1A). Because 
none of these ATGs has the characteristics of a typical translation start site (i.e. Kozak 
consensus sequence), we performed 5’ and 3’ rapid amplification of cDNA ends (RACE) 
to determine the full-length of the MC3R mRNA transcript. As we are exploring the role 
of MC3R in human lung diseases, we performed RACE upon mRNA extracted from 
bronchial epithelial cells from a CF patient (CFBE41o- cells).  
The 5’ RACE mapped the start site of transcription approximately 527 bp 5’ of 
the reference sequence of MC3R. The full-length transcript contains an additional 5’ exon 
of ~252 bp, labeled now as exon 1, and an intron of 248 bp (Fig. 2.1B). The original 
exon, re-labeled as exon 2, is 27 bp longer than previously predicted. The 3’ RACE 
verified that MC3R does not have any downstream exon and that a poly(A) tail is added 
116 bp downstream of the stop codon. The highly conserved canonical poly(A) signal 
AAUAAA was not found in the 3’ UTR. However, two potential poly(A) signals, 
AAGAAA and UAUAAA, were found 46 bp and 21 bp from the poly(A) tail, 
respectively.  
To confirm the RACE results, reverse-transcription PCR (RT-PCR) was 
performed using primers positioned in exons 1 and 2 of MC3R. DNA fragments of the 
expected size were obtained upon amplification of genomic DNA (gDNA) from human  
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Figure 2.1: Mapping of the 5’ transcription start site and the gene structure of 
MC3R. (A) The nucleotide locations of the first three in-frame start codons in the 
reference sequence of MC3R (NM_019888) are annotated using the Feb. 2009 (hg19) 
assembly of the human genome. The underlined sequence around each start codon 
demarcates the region inspected for correspondence to the Kozak consensus sequence 
(GCCGCCATGG).  (B) This diagram summarizes the gene structure of MC3R deduced 
from 5’ and 3’ RACE experiments. 5’ RACE found a novel exon upstream of the 
reference sequence of MC3R. A start codon was not detected in-frame. The original exon 
is 27 bp longer than previously predicted.  The 252+ bp upstream exon (labeled now as 
exon 1), 248 bp intron, and 1111 bp original exon (re-labeled as exon 2) all contained 
splicing consensus sequences. The diagram also illustrates the positions of the 3 pairs of 
MC3R primers used in RT-PCR. (C) The image shows agarose gel electrophoresis of 
ethidium bromide stained gDNA and cDNA fragments amplified by PCR. RT-PCR 
demonstrated that MC3R mRNAs from human brain tissue, HBE cells, and CFBE41o- 
cells include sequences from exon 1 and exon 2. The label on the top of each lane of the 
gel represents different primers that were used to amplify the product. Prior to RT, RNA 
was treated with DNase to eliminate the contaminating gDNA. The TBP primers were 
designed from two different exons with an intervening intron that is short enough to be 
amplified during elongation. The size of TBP band indicated that there is no gDNA 





lymphocytes and cDNA synthesized from primary human brain tissue (temporal lobe) 
mRNA (Fig. 2.1C). In gDNA and brain cDNA, the MC3R primer pair #1 amplified a 
fragment of 1084 bp that corresponded to the length expected from exon 2. Primer pair 
#2 amplified a 921 bp gDNA fragment and a 673 bp brain cDNA fragment that were 
extended from exon 1 to exon 2 consistent with the presence or excision, respectively, of 
the 248 bp intron. Primer pair #3 amplified a 476 bp brain cDNA fragment that extended 
from the exon 1 - exon 2 junction to exon 2 indicative of intron splicing. Primer pair #3 
generated only non-specific products upon amplification of gDNA, as expected.  These 
results show that MC3R contains an upstream intron that is excised in brain mRNA. The 
cDNAs synthesized from human bronchial epithelial (HBE) and CFBE41o- cell RNA 
were also studied. Each cell line generated amplification products identical to those 
obtained from amplification of brain cDNA (Fig. 2.1C). Thus, MC3R is composed of two 
exons that are spliced to form an mRNA of approximately 1363 bp in primary brain 
tissue and in pulmonary airway epithelial cells. 
 
Translation is initiated at the second in-frame ATG of MC3R.   
To determine if translation initiated at the first or second in-frame ATG (or 
elsewhere), we created a plasmid containing a full-length MC3R cDNA and then mutated 
the first two ATG codons to GCG. The full-length MC3R cDNA was created by joining 
exon 1 and exon 2 of MC3R via fusion PCR and was fused in-frame to a c-Myc epitope at 
the C-terminus to facilitate detection of translated protein. After the introduction of 
mutations to the first and/or second ATG and sequence verification, Madin Darby Canine 
Kidney (MDCK) cells were transiently transfected with each plasmid and expressed 
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protein was detected with an anti-c-Myc antibody. As a control for transfection, a 
plasmid encoding the MC2R-accessory-protein (MRAP) with a C-terminal FLAG epitope 
was co-transfected with each MC3R construct. 
Confocal microscopy revealed that MC3R protein is detectable in similar numbers 
of cells when the first ATG is intact or mutated (Fig. 2.2A and B). Most of the cells 
expressing wildtype MC3R or MC3R with the first ATG mutated also expressed MRAP 
(see merge panels). However, protein was not detected when the second ATG was 
mutated (Fig. 2.2C) or when both ATGs were mutated (Fig. 2.2D). Detection of cells 
expressing MRAP indicated that failure to detect MC3R protein when the second ATG 
was mutated was not due to transfection issues. These results indicate that translation of 
MC3R is initiated at the second ATG and the full-length protein encompasses 323 amino 
acids. This conclusion is consistent with cross-species conservation of the second but not 
the first ATG of MC3R and with studies of truncated 5’ MC3R fused to reporter protein 
that demonstrated preferential initiation from the second ATG (168).    
 
MC3R displays discrete apical and sub-apical localization in polarized MDCK cells.  
Expression of MC3R in non-polarized cells revealed membrane localization, as 
expected for a transmembrane signaling protein (123,145,152). MC3R is abundantly 
expressed in the neurons of adult rat brain (169), which are polarized cells that rely on 
discrete localization of specific membrane proteins (i.e. axonal vs. dentritic). Polarized 
MDCK cells distribute proteins in a pattern consistent with polarized neuronal cells as 
both cell types share many common mechanisms of protein targeting (i.e. apical/axonal 
and basolateral/dentritic) (170-172). To assess whether MC3R localizes to specific  
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Figure 2.2: MC3R translation begins at the second methionine.  Fluorescent 
photomicrographs of MDCK cells in x-y plane. Cells were transiently transfected with 
MC3R wildtype plasmid or plasmid that has the first and/or second ATG mutated to 
GCG and co-transfected with MRAP-FLAG as a transfection control. Cells were stained 
with anti-c-Myc antibody and secondary antibody linked to Cy3 (red) to detect MC3R 
and with anti-FLAG antibody and secondary antibody linked to Alexa Fluor 488 (green) 
to detect MRAP. The green fluorescence indicated that MRAP was expressed in 
approximately 5% of cells in each transfection.  In the merge row, red and green 
fluorescence were combined and DAPI was used to stain cell nuclei. (A) Wildtype MC3R 
is detected in most cells that express MRAP. (B) When the first ATG is mutated, MC3R 
is detected in about 90% of cells expressing MRAP. (C) MC3R is not detected when the 
second ATG is mutated. (D) When both the first and second ATG are mutated, MC3R is 




membrane compartments, the location of MC3R was investigated by confocal 
microscopy of polarized MDCK cells.  
Polarization of MDCK cells was verified by staining with anti-ZO-1 antibody, a 




 ATPase antibody, a marker for basolateral 
membrane surface. To mark the location of the apical membrane, the cells were co-
transfected with a plasmid expressing the CF transmembrane conductance regulator 
tagged with GFP at the N- terminus (GFP-WT-CFTR), a protein known to localize to the 
apical surface of MDCK cells (57,173,174). Confocal imaging of these cells revealed that 
the proteins were present in their expected locations (Fig. 2.3A and B). In this set of 
experiments, the cDNA encoding native MC3R was used to avoid aberrant localization 
due to the presence of an epitope tag. MC3R protein was detected with anti-MC3R 
polyclonal antisera directed against an 88-aa peptide from the N-terminus of MC3R 
(Santa Cruz). In 11 of 16 cells examined, MC3R displayed localization that was 
coincident with CFTR. The overlap of two proteins resulted in yellow fluorescence in the 
merge, demonstrating that MC3R is localized at the apical surface (Fig. 2.3C). In the 
remaining 5 cells, MC3R demonstrated localization to regions near the apical membrane; 
however, the distribution did not overlap with CFTR (Fig. 2.3D). Thus, MC3R primarily 
appears to be apically located in polarized cells either in the same region as CFTR or less 
often in a sub-apical compartment, suggesting axonal distribution in neuronal cells. 
 
Absence of the 5’ UTR results in translation initiation at the first in-frame ATG and 
synthesis of protein that is aberrantly localized in polarized MDCK cells.   
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Figure 2.3: MC3R exhibits apical localization in polarized MDCK cells. Confocal 
microscopy images of MDCK cells taken in the x-z plane with the bottom row in each 
panel representing the composite scan and the panels above showing red or green 
fluorescence. In the merge row, cells were counterstained with DAPI to detect the nuclei. 
(A) The cells were immunostained with anti-ZO-1 antibody, a tight junction marker, in 
red to demonstrate that apical-basolateral polarity is present. (B) Immunostaining of the 




 ATPase showed staining consistent with localization to 
basolateral membranes. (C) Localization of MC3R overlapped with that of CFTR in the 
majority of cells examined. (D) Localization of MC3R near the apical membrane did not 
overlap with CFTR in the minority of cells examined. AP = apical. BL = basolateral. 








To investigate whether the newly discovered 5’ UTR was responsible for the 
preferential use of the second in-frame ATG for translation initiation, exon 1 and 27 bp 
from the 5’ of exon 2 were removed to create a partial version of MC3R (parMC3R). The 
partial version corresponds precisely to the 1084 bp single exon of MC3R that is 
annotated by NCBI RefSeq Database (NM_019888). The parMC3R cDNA was 
subcloned into a vector with a C-terminal c-Myc tag to enable detection in transfected 
cells. The protein translated from the parMC3R cDNA displayed a cytoplasmic 
distribution in polarized MDCK cells (Fig. 2.4A) that was distinctly different from 
protein translated from the full-length cDNA (Fig. 2.3C and D). The detection of protein 
synthesized from the parMC3R cDNA by both the N-terminal antisera and the C-terminal 
epitope tag indicated that translation initiated somewhere within the first 88 aa and 
continued to the native C-terminus. As only the first and second in-frame ATGs lie 
within the region recognized by the N-terminal antisera, we mutated each ATG to assess 
where translation was initiated in the parMC3R cDNA. When the first ATG of this partial 
construct was mutated to GCG, the translated protein localized to the apical regions of 
the polarized MDCK cells (Fig. 2.4B), as noted for protein translated from second ATG 
of the full-length MC3R cDNA (Fig. 2.3C and D). When the second ATG of the partial 
construct was mutated to GCG, the resulting protein displayed a cytoplasmic distribution 
(Fig. 2.4C). From these results, we conclude that translation of parMC3R cDNA is 
initiated from the first ATG, generating a protein that does not localize to the cell 
membrane.  
Further studies were performed to exclude alternative explanations for the 
cytoplasmic location of MC3R protein translated from the first ATG. To test if the C-  
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Figure 2.4. In absence of the 5’ UTR, MC3R is mislocalized to the cytoplasm of 
polarized cells.  Confocal microscopy images of MDCK cells taken in the x-z plane. (A) 
MDCK cells were immunostained with anti-MC3R antisera in red and anti-c-Myc 
antibodies in green to detect the expression of a fusion protein, parMC3R-MYC. Protein 
synthesized from the partial exon 2 showed diffuse cytoplasmic distribution in polarized 
MDCK cells. Fluorescence from the anti-MC3R and anti-c-Myc staining overlapped 
almost completely (see merge panel). (B) When the first ATG of the partial construct was 
mutated to GCG, this led to translation initiation from the second ATG. Immunostaining 
with anti-ZO-1 antibody illustrated that this form of MC3R protein has discrete apical 
localization. (C) A form of MC3R is detected when the second ATG of the partial 
construct is mutated to GCG, but this protein displays diffuse cytoplasmic localization. 
(D) Staining with WGA outlined the plasma membrane. Immunostaining with anti-
MC3R antisera revealed that the untagged parMC3R has cytoplasmic localization under 
the cell membrane. (E) MDCK cells stably expressing GFP-WT-CFTR were 
immunostained with anti-GFP antibody to detect CFTR and with anti-HA antibody to 
detect HA-parMC3R. GFP-WT-CFTR protein was used as a marker for apical surface 
expression. The commercially available HA-parMC3R plasmid is missing the 5’ UTR 
and has the partial exon 2 of MC3R fused in-frame to the HA tag at the N-terminus, thus 
forcing the inclusion of the amino acids from the first to the second ATG. A diffuse 
cytoplasmic stain was observed for HA-parMC3R. These experiments reveal that the 
partial exon 2 of MC3R encodes aberrant forms of the protein that are distributed in the 
cytoplasm of polarized cells, which is distinctly different from the localization of the 
46 
 





















terminal tag interfered with protein biogenesis, the tag was removed. MDCK cells 
transfected with the untagged parMC3R plasmid were stained with WGA, a plasma 
membrane marker, and with the N-terminal anti-MC3R antisera. Protein encoded by the 
untagged parMC3R cDNA was cytoplasmic and did not co-localize with the cell 
membrane marker (Fig. 2.4D). We then transfected MDCK cells with a commercially 
available construct, labeled HA-parMC3R, that contains the partial exon 2 of MC3R 
fused in-frame to the HA epitope at the N-terminus (www.cdna.org). This construct was 
selected as it has been used in a number of functional studies of MC3R 
(131,145,151,175,176). Translated products from this vector include amino acids from 
the first ATG to the second ATG that we predict are not present in native MC3R. 
Staining of transfected cells with the anti-HA antibody revealed a diffuse cytoplasmic 
distribution in polarized MDCK cells that was distinct from apically located GFP-WT-
CFTR (Fig. 2.4E). Together, these studies indicate that the 5’ UTR from exon 1 and the 
5’ of exon 2 are essential for directing translation of a membrane localizing form of 
MC3R that begins at the second in-frame ATG.   
 
MRAP2 colocalizes with MC3R and MC2R in polarized cells.   
It has been shown that accessory proteins, MRAP and MRAP2, support cell 
surface expression of MC2R in non-polarized cells and interact with melanocortin 
receptors 1-5 to modulate signaling to intracellular second messengers (131). These 
single-pass transmembrane accessory proteins have been shown to localize at the cell 
surface as well as to the ER (177,178). However, the location of MRAP and MRAP2 in 
polarized cells has not been established. Also, it is not known if the accessory proteins 
48 
 
colocalize with melanocortin receptors in polarized cells. To address this issue, MRAP 
and MRAP2 were expressed in polarized MDCK cells by themselves and in the presence 
of MC3R, HA-parMC3R and HA-MC2R. The HA tagged version of MC3R was used as 
it localizes to a different cellular compartment than native MC3R.  
MRAP and MRAP2 displayed diffuse cytosolic distribution in polarized MDCK 
cells (Fig. 2.5A, B). The localization of MC3R remained the same in the presence of the 
accessory proteins, as it was observed at or near the apical surface of the cell (Fig. 2.5C-
E). Interestingly, the distribution of MRAP2 was substantially different when co-
expressed with MC3R whereas MRAP distribution was unchanged (Fig. 2.5D and E). 
MRAP2 was found at discrete locations that partially overlapped with MC3R in the 
apical membrane (see merged x-z image in Fig. 2.5E). On the other hand, HA-parMC3R 
did not affect the localization of MRAP2. MRAP and MRAP2 remained cytoplasmic 
when co-expressed with HA-parMC3R (Fig. 2.5G-H). When expressed alone, MC2R was 
localized in the cytoplasm of polarized MDCK cells (Fig. 2.5I). MC2R localization was 
unaltered when co-expressed with MRAP (Fig. 2.5J). However, the cellular distribution 
of both MC2R and MRAP2 was dramatically altered when co-expressed. Both proteins 
were localized to membranes with overlapping expression in the lateral membrane and 
primarily MC2R expression in the apical compartment (Fig. 2.5K). These results suggest 







Figure 2.5. MRAP2 is re-distributed in the presence of MC3R and MC2R. Confocal 
microscopy images of MDCK cells taken in the x-y and x-z planes. Each 
photomicrograph shows immunostained cells after transfection with the plasmid listed on 
the top (none, MRAP-FLAG, or MRAP2-FLAG) and the plasmid listed across the left 





ATPase, ZO-1 and MC3R along the top row and left column are labeled according to the 
color of the fluorescence. Nuclei were counterstained with DAPI in blue. For detection of 
proteins in the apical compartment, x-y sections were above the nucleus. For detection of 
cytoplasmic or basolateral proteins, x-y sections transected through the nucleus. (A) 
MRAP alone displays a diffuse cytoplasmic distribution. Red staining in a ‘chicken wire’ 
pattern corresponds to the staining of ZO-1 in tight junctions formed by polarized cells. 
(B) MRAP2 alone displays diffuse cytoplasmic staining in polarized MDCK cells. (C) 





 ATPase. (D) MRAP displays diffuse cytoplasmic distribution 
while co-expressed MC3R is localized near the apical membrane. (E) MRAP2 is 
localized to the plasma membrane in the presence of MC3R. (F) HA-parMC3R is 
expressed in the cytoplasm of polarized MDCK cells. (G) MRAP displays diffuse 
cytoplasmic distribution when co-expressed with HA-parMC3R. (H) MRAP2 
localization is unchanged in the presence of HA-parMC3R. (I) MC2R is in the cytoplasm 
of polarized MDCK cells. (J) MRAP and MC2R show partial overlap in the cytoplasm. 
(K) MRAP2 displays localization to the plasma membrane when co-expressed with 
MC2R. MC2R is found in apical and lateral membranes while MRAP2 is primarily 


















In this study, we characterized the transcription and translation start sites of 
human MC3R and determined its localization in the presence or absence of MRAPs in 
polarized cells. Our results indicate that MC3R is a two-exon gene that requires a long 5’ 
UTR for translation initiation from the second in-frame ATG. Furthermore, MC3R 
translated from the second ATG is apically located while protein that initiates at the first 
ATG remains cytoplasmic in polarized cells.  
Colocalization of MC3R and MRAP2 at the cell membrane raises the possibility 
that MRAP2, in addition to being an accessory factor for MC2R, can affect the function 
of MC3R and influence human phenotypes. As several variants in MC3R have already 
been implicated in obesity, hypertension, tuberculosis susceptibility, lung inflammation, 
and pulmonary variation in CF (112,115,123,125,158-165), elucidation of MC3R gene 
structure and protein localization is a critical step in interpreting its role in human 
diseases and conditions. 
Incomplete annotation of the 5’ regions of human as well as mouse genomes 
illustrates an urgent need to experimentally validate the gene architecture (179-183). 
Experimental examination of transcriptional start sites of 106 mouse genes by 5’ RACE 
revealed that more than half of the genes produced sequences that were longer than the 
predicted annotation (179). In the case of MC3R, we identified a novel upstream exon 
that extends the length of the 5’ UTR without changing the ORF. The discovery of a 
noncoding first exon of MC3R should not be a surprise since approximately 40% of the 
known human genes have noncoding first exons (184). Determining the transcription start 
site of MC3R, and therefore its promoter region, is of great interest since MC3R is 
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involved in the regulation of numerous physiological processes. Though it is known that 
both enhancer and suppressor elements can be found tens of thousands of bases upstream 
or downstream from the transcription start site (185), most essential control elements are 
usually present within the proximal promoter (186). Moreover, UTRs have been known 
to regulate the synthesis of a protein by affecting mRNA stability (187), translation 
efficiency (188), and protein trafficking (189). Changes in the length or the sequence of 
the 5’ UTR have been implicated in various human diseases, such as hereditary 
thrombocythemia (190) and X-linked Charcot-Marie-Tooth disease (191). Identification 
of native transcription start site is essential in defining the location of the promoter and 
exploring cis-regulatory elements that control gene expression. 
 Prior to the discovery of this upstream exon, the first ATG was an unlikely 
translation start site because the 5’ UTR, consisting of one nucleotide, would not provide 
enough space for binding of various trans-acting assembly factors. While evolutionarily 
conserved across vertebrates, the second ATG is followed by a poor Kozak sequence and 
lacks an optimal context for ribosome recognition. In Feb. 2011, Ensembl listed two 
transcripts under MC3R (http://feb2011.archive.ensembl.org/), but the second transcript 
was removed in Apr. 2011 (http://apr2011.archive.ensembl.org/). Interestingly, both 
MC3R transcripts were predicted to contain only one exon but differed in their translation 
start sites. The MC3R transcript that is currently listed on Ensembl labels the second in-
frame ATG as the translation start site based on cross-species conservation. In spite of the 
current annotation, most of the previous literature on MC3R assumes that translation 
begins at the first ATG and therefore the SNPs are named by counting from the first 
methionine. For example, two common MC3R variants, rs3746619 and rs3827103, that 
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have been frequently investigated are referred to as T6K or V81I variant, respectively 
(125,159,192-195). As our results confirm that proper translation of MC3R begins at the 
second ATG, located 37 amino acids downstream of the first ATG, rs3746619 (ie T6K) 
should be considered as a SNP in the 5’ UTR that has variable association with obesity, 
not a missense variant.   
While it is thought that translation initiates at the first ATG in most eukaryotic 
genes, upstream ATGs are found in 15% to 50% of the 5’ UTRs depending on the 
organism (196). This reveals that deviations from the “first-ATG rule” may be more 
common than we may have appreciated. There are several possible reasons for why 
translation initiates at the second ATG in MC3R. The sequence context around the first 
ATG may be far from optimal for initiating translation, resulting in leaking scanning of 
the ribosome (197). A hairpin secondary structure downstream of the first ATG may stall 
the ribosome and increase the likelihood of recognizing the second ATG (198). The 
upstream ATG found in the 5’ UTR of MC3R may be in involved in ensuring low basal 
translational level, as it has been demonstrated that cDNAs with long 5’ UTRs with 
several upstream ATGs have a weak start context (199,200). Moreover, upstream ORFs 
have been correlated with significantly reduced protein expression of the downstream 
ORF (201). Given that variants that create a polymorphic upstream ORF, which alters 
cellular expression of the downstream protein, have already been identified in MC2R 
(201), discovery of such variants in MC3R can potentially explain the mechanism that 
affects protein expression and perhaps phenotypic variation. 
The significance of the 5’ UTR in MC3R goes beyond regulating its translation 
initiation because our data indicate that protein localization is also affected by the 
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methionine that is used to initiate translation. To investigate the localization of MC3R, 
we used polarized MDCK cells that have been extensively used as a model for studying 
the sorting of membrane proteins (170,202,203). Our study demonstrates that MC3R is 
localized at or near the apical surface in polarized MDCK cells. In contrast, MC3R 
produced from partial constructs that lack the 5’ UTR displays cytoplasmic distribution, 
indicating that the protein is unable to efficiently localize to the cell surface. Previous 
studies that used the parMC3R constructs as well as the commercially available HA-
parMC3R plasmid to study localization in non-polarized cell types concluded that this 
form of MC3R displays cell surface as well as intracellular expression (123,145,146). We 
have demonstrated that the absence of the 5’ UTR causes incorrect usage of the first ATG 
for translation initiation. Therefore, we conclude that the partial constructs and the HA-
parMC3R plasmid synthesize a protein that incorrectly includes the sequence between the 
two start codons, resulting in a distinctively different localization pattern as compared to 
native MC3R. While epitope tagging can be powerful and convenient in rapid analysis of 
protein function, it can interfere with the function or cellular processing of the tagged 
protein. For example, it has been shown that GFP-tagging of human acetylcholine 
receptor alters the channel property in Xenopus oocytes (204) and glycosylation of 
angiotensin type II receptor were affected by epitope tagging in HEK293 cells (205). This 
emphasizes the importance of understanding the potential impact of epitope tagging on 
protein expression and use of constructs that represent the true context of the native 
protein. 
The signaling and trafficking properties of GPCRs are regulated by the receptor-
interacting proteins that are differentially expressed in distinct cell types (206). Our study 
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reveals that MC3R may interact with MRAP2, suggesting that MRAP2 has unknown 
roles besides being an accessory protein for MC2R. This result is consistent with a 
previous study, which demonstrated that MRAPs can downregulate the expression and 
signaling of MC3R (131). These studies raise the questions of how and why MRAP2 
interacts with other melanocortin receptors. It is possible that this interaction may vary in 
a cell-type specific manner and in response to changes in the environment. In contrast to 
MRAP2, MRAP does not colocalize with MC3R at the plasma membrane and is unable 
to assist in functional expression of MC2R in MDCK cells. Since it has been noted that 
functional expression of MC2R is challenging as it can only be achieved in cells of 
adrenal origin (207), the failure of MC2R to reach the plasma membrane in the presence 
of MRAP in our study may be due to the cell type that was used. Additional factors, such 
as unidentified accessory proteins, may be required to facilitate trafficking of MC2R or 
MC3R and MRAP to the cell surface in this specific polarized cell system. As our data 
indicates that MRAP2 could be an accessory protein that influences functional expression 
of MC3R, provided that these proteins are co-expressed in vivo, further work will be 
needed to investigate the mechanism by which MRAP2 modulates the function of MC3R. 
In summary, our results indicate that MC3R is a two-exon gene that requires its 5’ 
UTR for proper translation, localization, and potential interaction with MRAP2. Our 
study defines the native gene structure and the protein expression of MC3R, an important 
member of the melanocortin family that plays an integral role in numerous physiological 





Materials and Methods 
Cell culture  
Human bronchial epithelial (HBE) cells and CF bronchial epithelial (CFBE41o-) cells 
carrying homozygous F508del CFTR mutation were maintained in Minimum Essential 
Medium (Gibco). Madin Darby Canine Kidney (MDCK) cells were maintained in 
Dulbecco's Modified Eagle's Medium (DMEM) (Cellgro). MDCK cells stably expressing 
GFP-WT-CFTR were maintained in DMEM with 100 μg/ml hygromycin (Invitrogen). 
All media were supplemented with 10% FBS (Cellgro) and 1% penicillin-streptomycin 
(Gibco) at 37°C in an atmosphere of 5% CO2. 
 
RNA isolation  
Total RNA was isolated from human brain tissue, HBE cells, and CFBE41o- cells by 
using RNeasy Mini Kit (Qiagen) as described by manufacturer’s protocol. It was then 
treated with DNA-free DNase (Ambion) to remove contaminating DNA as described by 
manufacturer’s protocol.  
 
Rapid amplification of 5’ and 3’ cDNA ends (RACE) 
5’ and 3’ RACE were performed using SMARTer
TM
 RACE cDNA Amplification Kit 
(Clontech), as described by manufacturer’s protocol. The mRNA extracted from 
CFBE41o- cells was used for RACE. The gene-specific primers (GSP) were designed on 
the plus and minus strands of the reference sequence of MC3R (NM_019888). MC3R 
cDNA was amplified with a universal primer and MC3R-specific primer. Nested PCR 
amplification was subsequently performed with the nested universal primer and the 
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nested MC3R-specific primer to confirm the specificity of the primary PCR products. The 
nested PCR products were gel purified and sequenced with Applied Biosystems 3730xl 
DNA Analyzer.  
 
Reverse transcription PCR (RT-PCR) 
DNase-treated RNA was reverse-transcribed using iScript™ cDNA Synthesis Kit (Bio-
Rad). PCR was performed using Taq DNA Polymerase (Invitrogen). Following a 6-min 
denaturation at 95°C, 40 cycles of 95°C for 45 s, 59°C for 45 s and 72°C for 1 min were 
performed, followed by a 10-min extension at 72°C. RT-PCR products were visualized 
by agarose gel electrophoresis with ethidium bromide staining. 
 
Plasmids  
The full-length MC3R plasmid was generated by amplifying exon 1 and exon 2 of MC3R 
from genomic DNA. The 260-bp exon 1 band and 1131-bp exon 2 band were extracted 
from the gel and re-amplified via fusion PCR to connect the two overhanging products. 
The 1391-bp fusion amplicon was then subcloned into a StrataClone Mammalian 
Expression Vector, pCMV-SC-CM, that contains a C-terminal c-Myc epitope tag vector 
(Agilent). The parMC3R-MYC plasmid was created by subcloning the known reference 
sequence of MC3R (NM_019888) into a StrataClone Mammalian Expression Vector with 
a C-terminal c-Myc tag, pCMV-SC-CM (Agilent). The sequences of each construct were 
verified by Sanger sequencing. The GFP-WT-CFTR plasmid was generated by removing 
full-length cDNA from the existing peGFP-CFTR plasmid by enzyme digestion and 
ligating into the multiple cloning sequence of the pcDNA5/FRT vector (Invitrogen). The 
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pcDNA3.1 plasmids encoding MC2R or partial MC3R with a 3× HA tag on the N 
terminus (HA-MC2R and HA-parMC3R) were purchased from Missouri S&T cDNA 
Resource Center (www.cdna.org). MRAP-FLAG and MRAP2-FLAG plasmids were 




The first and/or second in-frame ATG was changed to GCG using QuikChange II XL 
Site-Directed Mutagenesis Kit (Agilent), as described by manufacturer’s protocol. To 
prevent the c-Myc tag of parMC3R-MYC plasmid from being expressed, nonsense 
mutations were introduced at the end of the partial MC3R sequence.  
 
Transfection 
MDCK cells were plated on the glass coverslips inside 12-well plates. When the cells 
were nearly 90% confluent, they were transiently transfected with 3.2 μg of a single 
plasmid or co-transfected with 1.6 μg of each of the two plasmids along with 4.8 μl 
Lipofectamine 2000 (Invitrogen), as described by manufacturer’s protocol. Cells were 
fixed two days after transfection. 
 
Immunocytochemistry and confocal microscopy  
Two days after transient transfection, cells were fixed in 3.7% formaldehyde for 20 min. 
Staining with WGA (Molecular Probes W11262) was performed prior to 
permeabilization by incubating the cells in diluted WGA (1:100) for 5 min. Staining with 
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antibodies was performed after the cells were permeabilized with 0.5% Triton X-100 for 
5 min and blocked with 2.5% goat serum for 30 min. The following primary antibodies 
were used for various proteins: HA (Sigma), c-Myc (Sigma), FLAG (Sigma), MC3R 





(Millipore). The secondary antibodies were respectively conjugated to anti-mouse or anti-
rabbit Alexa Flour 488 (Invitrogen) or Cy3 (Sigma). The primary and secondary 
antibodies were diluted to 1:200 and 1:50, respectively, in blocking buffer. The cells were 
incubated with primary antibodies for an hour, washed 3 times for 5 min each, incubated 
with secondary antibodies for an hour, and washed 4 times for 15 min each. ProLong 
Gold Antifade Reagent with DAPI (Molecular Probes) was used to stain the nuclei and 
mount the cells. Fluorescence was imaged using a Zeiss LSM510 confocal microscope at 








































Family-based studies have been used to estimate genetic and nongenetic 
contributions to disease severity in CF. Using affected twins and siblings, heritability of 
lung function severity has been estimated to be 0.54-1 using cross-sectional and 
longitudinal measures of lung function in CF (104). The higher concordance of lung 
function in monozygotic twin pairs and the high estimate for heritability of lung function 
in affected siblings validate the importance of searching for CF modifier genes (82). 
Identification of the modifier genes and their encoded products will help us better 
understand the pathogenesis of CF and could lead to potential therapeutic targets. 
To identify genetic modifiers, both genome-wide association and linkage 
approaches have been used (107,208-210).  Using 486 affected sibling pairs enrolled in 
the family-based CF Twin and Sibling Study (TSS), genome-wide association and 
linkage studies identified a significant modifier locus of lung disease severity at 
chr20q13.2 (LOD = 5.03) (112). This result was followed by SNP association testing in 
the linked region using unrelated individuals with two severe CFTR alleles from the 
Genetic Modifier Study and the Canadian Consortium for Genetic Studies (112). In the 
1.3 Mb region of linkage, as demarcated by 1 LOD unit below the maximum, two 
clusters of SNPs met regional association. A 16-kb cluster of SNPs in high LD was 
located in a gene desert centromeric to five genes: CBLN4, MC3R, AURKA, CSTF1 and 
CASS4. A second smaller cluster of SNPs was identified over MC3R. Of the five genes 
within the 1.3 Mb region of maximum linkage, MC3R was prioritized for follow-up 
based on the association evidence, its known role in the inflammatory pathway (115,116), 
its association with tuberculosis susceptibility (163,164), and its contribution to energy 
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metabolism (161,211,212). Furthermore, an empiric screen for new CF therapies using 
siRNAs revealed that reduction of MC3R resulted in restoration of chloride channel 
activity in cells expressing CFTR bearing the most common CF mutation, F508del (128).  
To define the mechanism of lung disease in CF that underlies the linkage signal at 
chr20q13.2, MC3R was evaluated as a potential modifier of lung function in CF. We first 
searched for variants and SNP haplotypes in MC3R that associate with lung disease 
severity. Pulmonary function in CF was defined by age- and sex- specific forced 
expiratory volume in one second (FEV1), a surrogate for survival in CF (113,213). The 
consequences of MC3R variants demonstrating association with lung function were 
assessed by in silico prediction tools. In vitro functional studies were also performed to 
determine the levels of MC3R mRNA transcripts carrying rare variants. Moreover, we 
evaluated whether or not the pro-inflammatory signaling pathway, which is altered in CF 
patients, can be mediated by MC3R agonist or siRNA. Lastly, we confirmed the presence 
of MC3R in primary airway epithelial cells of the lungs, further promoting the potential 
of MC3R to be a modifier of lung function in CF. The results of these approaches 
indicate that MC3R modulates the inflammatory pathway and affects lung function 
severity in CF. Gaining a mechanistic understanding of the cross-talk between MC3R and 
pro-inflammatory cytokines may be critical to developing new therapies to modulate lung 








Rare variants in MC3R associate with lung function in CF siblings 
To identify common and rare variants, a 1.8 kb region of genomic sequence that 
includes both exons and the intervening intron of the MC3R gene was analyzed in 151 
sibling pairs with CF by Sanger sequencing. The siblings were selected from the family-
based Twin and Sibling Study (TSS) (104,112). We selected sibling pairs who have 0 or 
2 copies of the alleles identical by descent (IBD=0 or 2) at MC3R, because we 
hypothesized that a sibling pair that shares both alleles at MC3R will have a greater 
probability of sharing variants that contribute to lung functions than sibling pairs that 
share no alleles. The siblings carried at least one copy of F508del allele, the most 
common CFTR mutation, in order to minimize the effect of CFTR heterogeneity on lung 
function.  
A total of eight variants were identified in MC3R (Fig. 3.1). Three variants are 
located in the 5’ UTR of MC3R and one variant is found in the intron (Fig. 3.1A). Four 
variants are found in the coding region of MC3R (Fig. 3.1A). Of the eight variants, four 
variants have minor allele frequencies (MAF) less than 1%. Two of the four rare variants 
– g.54823323T>G and g.54824368A>C (p.T157P) – are novel. Seven individuals (2 pairs 
of IBD=2 siblings and 3 unrelated IBD=0 individuals) have one heterozygous rare 
mutation (Fig. 3.1B). The relative MAF of the variants in MC3R met the requirements of 
Hardy-Weinberg equilibrium and did not differ from those reported in public databases of 





Figure 3.1: Characteristics of common and rare variants in MC3R. (A) Diagram of 
human MC3R gene and the approximate positions of the variants. The amino acid change 
of each applicable variant is shown. The location of ATG represents the translation start 
site. (B) Summary of variants identified in MC3R.  The change in nucleotide and/or 
amino acid sequence for each variant is described in the table. European individuals from 
phase 3 of the 1000 Genomes Project were used to calculated the MAF. Family ID 
followed by a letter (A or B) is used to denote the individuals with or without variants. 








To assess the association of the variants to lung disease severity, we tested the 
minor alleles using linear regression. Lung disease severity was quantified using 
SaKNorm, a survival-adjusted average of CF-specific percentiles for FEV1 using three 
years of data (112). These analyses used the Z-score corresponding to a given percentile, 
related by normal transformation. Significant association with lung disease severity as 
measured by FEV1 was observed for three rare variants located in the coding region: 
g.54824368A>C (p.T157P), rs41274722 (p.I189I), and rs61735259 (p.R220S) (Table 
3.1) (Fig. 3.2). None of the common variants was associated with lung function.  
To evaluate whether the MC3R alleles identified by Sanger sequencing could 
explain the former linkage signal on chr20q13.2, we assessed the LOD score 
contributions of the individuals carrying the rare variants that were significantly 
associated with lung function. One IBD=2 sibling pair carrying rs41274722 (p.I189I) 
contributed positively to the LOD score. However, the remaining three sibling pairs had 
negative LOD scores: one IBD=0 pair in which one sibling carries g.54824368A>C 
(p.T157P) and two IBD=0 pairs in which one sibling per pair carries rs61735259 
(p.R220S). There is insufficient evidence that the rare variants in MC3R are responsible 
for the linkage signal on chr20q13.2. 
 We next performed haplotype analysis to assess whether a particular combination 
of common and rare variants was associated with lung function. Haplotype analysis 
revealed that MC3R belongs in one block exhibiting moderate linkage disequilibrium 
(LD) (Fig. 3.3A-B). SNPs rs3746619 and rs3827103 are in complete LD, but rs6127698 
and rs11575886 show partial LD. The correlation values (r
2
 and D') and haplotype 
frequencies derived for the CF siblings are concordant with those of the HapMap3 CEU  
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0.624 0.499 0.177 0.315 0.315 0.043* 0.024* 0.007* 
ΔZ-score N/A N/A N/A N/A N/A 1.58 -1.25 1.49 


















Figure 3.2: Histogram of CF patients according to lung disease severity. Lung 
disease severity was quantified by FEV1 percentile, which was transformed to z-score. 
The green arrows represent three unrelated individuals with rare variants that were 
associated with higher lung function. The red arrows represent the sibling pair who carry 
p.I189I variant, which was shown to be associated with poor lung function. The black 
arrows represent the sibling pair who carry the g.54823323T>G variant that was not 







Figure 3.3: LD plots across the MC3R locus generated by Haploview. Based on the 
criteria defined by Gabriel et al. (214), one haplotype block was identified for variants in 
MC3R. (A) LD plot based on r
2
. The physical position of each variant is presented in the 
upper diagram. Each box provides estimated statistics of pairwise r
2
 values, with darker 
shades representing stronger LD. r
2
 = 1 (black) means complete LD. (B) LD plot based 
on D'. D' values are given in the cell intersecting each pair of SNPs. The LD color 
scheme is stratified according to the LOD score and D': LOD <2 (white for D'<1 and blue 
for D' = 1) or LOD >2 (shades of pink/red for D'<1 and bright red for D' = 1). (C) Four 









































population. Of the eight haplotypes identified in MC3R, four major haplotypes (labeled A 
– D) account for almost 99% of the variation (Fig. 3.3C). Two haplotypes (labeled D1 and 
D2) carrying the rare variants, rs41274722 (p.I189I) or rs61735259 (p.R220S), are 
derived from haplotype D. The third rare haplotype (labeled B1) with g.54823323T>G 
change rose from haplotype B. Due to missing parental haplotypes, we were not able to 
distinguish between A or G at rs11575886 for the fourth rare haplotype (labeled B2 or C1) 
with g.54824368A>C (p.T157P) variant. Haplotypes D1, D2 and B1 were each observed 
on two chromosomes. Haplotype B2 (or C1) was present on one chromosome. Omnibus 
tests of the common (df = 3, p = 0.357) haplotypes did not reveal any association with 
lung function though the presence of rare variants seem to drive the haplotypic effects 
seen in haplotypes D2 and B2 (or C1) (df = 7, p = 0.027) (Table 3.2). Independent effects 
of rare SNPs on a major haplotype background were not possible as these variants were 
underrepresented in our population (seen in a maximum of 2 pedigrees). 
 
In silico and functional characterizations of coding variants in MC3R demonstrate 
that g.54824368A>C (p.T157P) may be deleterious 
The potential pathogenicity of the four coding variants was assessed using in 
silico prediction tools, such as SIFT, PolyPhen2, Condel and GERP (Table 3.3). The 
rs3827103 (p.V44I), a common variant, has been shown to have ligand binding and 
signaling properties similar to wildtype MC3R, and was unsurprisingly predicted to be 
benign (215). Whereas g.54824368A>C (p.T157P) was consistently found to be 
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G A A A 
   
0.223 
F-statistic overall p-value 
        
0.357 
Haplotype A T T A C G A T C 0.754 
Haplotype B T G A C G A T C 0.881 
Haplotype C T G G C G A T C 0.265 
Haplotype D  T G A A A A T C 0.311 
Haplotype D1 (p.I189I) T G A A A A A C 0.0245 
Haplotype D2 (p.R220S) T G A A A A T A 0.101 
Haplotype B1 (g.54823323T>G) G G A C G A T C 0.637 
Haplotype B2 or C1 (p.T157P) T G ? C G C T C 0.041 
F-statistic overall p-value 
        
0.027 
* for that haplotype against all others 












Table 3.3: In silico predictions for pathogenicity of the coding variants in MC3R.  












0.19 0.098 0.033  
4.05 
tolerated  benign neutral 



















aSIFT: range from 0 to 1. The amino acid substitution is predicted to be damaging if the score is <= 0.05 and tolerated if the score is > 
0.05.  
bPolyPhen2: range from 0 to 1. The amino acid substitution is predicted to be probably damaging if the score is close to 1.  
cCondel assesses the outcome of nonsynonymous variant by using a consensus deleteriousness score that combines SIFT, PolyPhen2 
and MutationAssessor.  
dGERP is a method for producing position-specific estimates of evolutionary constraint using maximum likelihood evolutionary rate 
estimation. GERP score ranges from -12.36 to 6.18. Positive scores represent a substitution deficit (i.e., fewer substitutions than the 



























algorithms. Based on the positive GERP score, the synonymous variant rs41274722 
(p.I189I) seems to be under evolutionary constraint.  
To test the effect of the rare coding variants on MC3R mRNA expression, we 
measured the mRNA levels by qPCR (Fig. 3.4). RNA was extracted from human 
transformed lymphocytes of rare variant carriers, their siblings, and two additional 
individuals without any rare variants. Unlike the housekeeping genes TBP and PPIA, the 
level of MC3R mRNA was low in all samples. The presence of g.54824368A>C 
(p.T157P) variant in 419B decreased the level of MC3R mRNA compared to the sibling 
without the variant, 419A. Interestingly, the presence of a missense variant at rs61735259 
(p.R220S) in 209A increased the level of MC3R mRNA compared to the sibling without 
the variant, 209B. The sibling pair 480A and 480B have the same MC3R genotype as 
they both carry a synonymous change at rs41274722 (p.I189I). However, we observed a 
large difference in the mRNA level of MC3R, suggesting that other factors may be 
involved in regulating the expression of this gene. Given that the sibling pair that is 
IBD=2 across MC3R has different levels of MC3R transcript, we are unable to interpret 
the result of IBD=0 sibling pairs. We will need to further investigate the effect of the rare 
variants on MC3R transcript levels using additional sibling pairs. 
 
Modulation of MC3R alters NF-κB-mediated reporter gene expression   
Previous investigations have demonstrated that melanocortin receptors, primarily 
MC1R and MC3R, are involved in the inflammatory pathways (116,121,144,216,217). 
Given that NF-κB is responsible for transcription of numerous cytokines that are involved 
in inflammation, we asked if modulation of MC3R can alter NF-κB-driven cytokine  
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Figure 3.4: Differential mRNA expression of MC3R in human transformed 
lymphocytes. MC3R mRNA expression was normalized to TBP and PPIA. Error bars 













expression. To determine the dose and incubation length of siRNAs for effective 
reduction of MC3R in K562 cells, we tested a range of MC3R siRNAs (0-100 pmol) and 
collected the lysates 2-4 days post transfection. Four days following transfection, MC3R 
siRNAs were successful in reducing the level of MC3R by 79% (Fig. 3.5A). 
 It has been reported that melanocortin receptors suppress NF-κB (121). Since the 
CMV promoter has four binding sites for NF-κB (218,219), we hypothesized that 
reduction of MC3R would prevent inhibition of NF-κB, which would allow the 
transcription factors to bind and activate the CMV promoter. In this study, we used CFTR 
as a reporter to measure NF-κB-activated CMV promoter function (Fig. 3.5B). K562 
cells were initially transfected with siRNAs on Day 0, subsequently transfected with 
various CFTR plasmids driven by the CMV promoter on Day 2, and lysed on Day 4. 
When MC3R expression was significantly decreased by MC3R siRNAs (Fig. 3.5C), we 
observed a 3-5 fold increase in the level of GFP-WT-, GFP-F508del- and F508del-CFTR 
(Fig. 3.5D). These results suggest that reduction in MC3R protein increases NF-κB 
activity in K562 cells consistent with findings in airway epithelial cells (116). 
 
Modulation of MC3R alters NF-κB-driven cytokine expression  
NF-κB drives expression of pro-inflammatory cytokines, such as interleukin (IL)-
8, that are known to be elevated in CF (220-222). Thus, we wanted to determine if 
modulating NF-κB by reducing MC3R expression would alter IL-8 levels. We 
determined the proper dose and incubation length of phorbol 12-myristate 13-acetate 
(PMA) that stimulates IL-8 expression in K562 cells. Various concentrations of PMA 
(0.2 – 5 ng/ml) were used to treat the cells, and serum IL-8 levels were measured by 
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Figure 3.5: Reduction in MC3R expression using siRNAs increases NF-κB-mediated 
reporter gene expression in K562 cells. (A) K562 cells were transfected with 0, 50 or 
100 pmol of MC3R siRNAs. Cell lysates were collected 2, 3 or 4 days post transfection. 
The level of MC3R expression was normalized to GAPDH. After 4 days, 100 pmol of 
MC3R siRNAs was effective in reducing the expression of MC3R by 79%. Error bars 
represent s.e.m. calculated from four independent experiments. *P < 0.05 relative to 
control. ** P < 0.005 relative to control. (B) The CMV promoter contains four binding 
sites for NF-κB transcription factors. CFTR is used as a reporter to quantify NF-κB-
activated CMV promoter function. (C) K562 cells were transfected with negative (no 
siRNA, negative control siRNA #1 or #2) or MC3R siRNAs. Two days later, the cells 
were transfected with three types of CFTR plasmids driven by the CMV promoter: GFP-
WT-CFTR (dark grey bar), GFP-F508del-CFTR (grey bar), or F508del-CFTR (light grey 
bar) plasmid. Cells were lysed 4 days after initial transfection. When K562 cells were 
transfected with MC3R siRNAs, there was a 40-79% decrease in MC3R expression by 4 
days post transfection. (D) When the level of MC3R has been significantly reduced in 
K562 cells, there is a 3 to 5-fold increase in the level of CFTR protein: GFP-WT-CFTR 
(298%, p<0.0001), GFP-F508del-CFTR (479%, p<0.03) and F508del-CFTR (336%, 
p<0.04). Error bars represent s.e.m. calculated from three independent experiments.* P < 






ELISA at different timepoints (0 – 6 hours). PMA evoked a dose- and time-dependent 
secretion of IL-8 in K562 cells (Fig. 3.6A). PMA-induced IL-8 production was 
significantly increased in K562 cells in which MC3R expression has been reduced by 
siRNAs (Fig. 3.6B). Combining this result with prior observations, we concluded that a 
decrease in MC3R protein results in an increase in NF-κB, which then induces the 
expression of IL-8 upon PMA stimulation. We next asked if activation of MC3R via 
agonist binding would decrease IL-8 expression upon PMA stimulation. Administration 
of a selective MC3R agonist, [D-Trp
8
]-γ-MSH, inhibited IL-8 expression in a dose-
dependent manner in K562 cells (Fig. 3.6C). Taken together, altering MC3R expression 
by RNAi or agonist binding changes IL-8 levels following stimulation with PMA. 
  
MC3R is expressed in the apical region of airway epithelial cells of normal and CF 
lung tissues.  
If MC3R modifies lung function in CF, we hypothesized that MC3R may be 
expressed in the lung. We elected to analyze the expression of MC3R in normal and CF 
lung tissues by immunohistochemistry. Lung tissues were stained with two antibodies 
that recognize different epitopes on MC3R. Immunohistochemical staining of the normal 
and CF lungs revealed the presence of MC3R in the airway epithelial cells (Fig. 3.7C-F). 
The enlarged images in the inset showed intensity at the apical border in both normal and 
CF lungs. The same staining pattern was detected by two different MC3R antibodies, 
further validating its expression in airway lungs. The Abcam anti-MC3R antibody that 





Figure 3.6: Modulation in MC3R expression followed by PMA stimulation alters 
NF-κB-driven cytokine expression in K562 cells. (A) K562 cells were incubated with 
different concentrations of PMA for 1, 3 or 6 hours. IL-8 levels were measured by 
ELISA. PMA induced IL-8 expression in a dose- and time-dependent manner. (B) K562 
cells were transfected with no siRNA, negative control siRNA #1 or #2, or MC3R 
siRNAs. Four days after transfection, the cells were incubated with 0.5 ng/ml or 1 ng/ml 
of PMA for 6 hours. PMA-induced IL-8 production in supernatants of K562 cells was 
measured by ELISA. Error bars represent s.e.m. calculated from two independent 
experiments of 0.5 ng/ml PMA treatment or four independent experiments of 1 ng/ml 
PMA treatment. (C) K562 cells were incubated with increasing concentration of [D-
Trp
8
]-γ-MSH for 12 hours and then with PMA for 6 hours. PMA-induced IL-8 levels 
were measured by ELISA. Error bars represent s.e.m. calculated from five independent 










to determine that staining is specific (Fig. 3.7G-H). Elimination of the signal with the 
blocked antibody indicated that staining is specific to MC3R. 
Given that CFTR is known to be expressed in surface airway epithelial cells of the 
lungs (223-225), we asked if MC3R is expressed in the same cell type as CFTR. Western 
blot demonstrated that MC3R protein is present in primary airway epithelial cells 
obtained directly from lung transplants from 5 individuals (Fig. 3.7I). Interestingly, 
variability in the level of MC3R expression did not correlate with the CFTR genotype 


















Figure 3.7: Western blot and immunohistochemical staining reveal that MC3R is 
expressed in the airway epithelial cells of normal and CF lung tissues. The formalin-
fixed, paraffin-embedded lung sections were detected by Dako EnVision
TM
+ System-
HRP, stained with hematoxylin, and visualized with a Nikon Eclipse 50i microscope at 
indicated magnification. Inset: higher magnification showing representative area. 
(Normal; n=2) (CF; n=2) 
(A, B) A universal negative control for rabbit primary antibody, which contains 
immunoglobulin fraction of serum from non-immunized rabbits, was used to ascertain 
nonspecific binding and help interpret specific staining at the antigenic site. In both 
normal and CF lung tissues, there was an absence of non-specific binding with the 
negative control. (C, D) Positive staining was observed on the apical region of the airway 
epithelial cells of normal and CF lung tissues with anti-MC3R antibody from LS Bio. (E, 
F) Similarly, positive staining was observed in the brush border of the airway epithelial 
cells with anti-MC3R antibody from Abcam. (G, H) Neutralizing the Abcam antibody 
with the blocking peptide abolished the signal in both normal and CF lung tissues. (I) 
Western blot of cell lysates from the temporal lobe of human brain and the primary 
airway epithelial cells. The temporal lobe was used as a positive control for Western blot 
analysis of MC3R expression. Their CFTR genotypes are indicated above each lane. (J) 
A variable expression of MC3R was observed in the primary airway epithelial cells 





















Our search for a modifier of lung function in CF has focused upon a 1.3 Mb 
region on chr20q13.2. This region contains five genes among which MC3R is a 
promising candidate gene for modifying lung function in CF due to its known role in 
inflammation (115,116) and its effect on energy homeostasis (123-125). We hypothesized 
that MC3R may be responsible for regulating lung inflammation and ultimately affecting 
lung function in CF. Identification of three rare variants in MC3R that displayed 
significant association with lung function in individuals with CF provided evidence that 
variation in MC3R contibutes to CF lung disease severity. In silico prediction tools as 
well as qPCR analysis suggest that two of the three rare variants, g.54824368A>C 
(p.T157P) and rs61735259 (p.R220S), may affect MC3R function. Based on prior studies 
demonstrating that melanocortin receptors modulate NF-κB activity, we showed that 
reduction in MC3R increases the level of CMV promoter-driven CFTR. The 3- to 8-fold 
increase in PMA-induced IL-8 level after decreasing the expression of MC3R supports 
our hypothesis that MC3R alters pro-inflammatory signaling through NF-κB. The 
presence of MC3R in primary airway epithelial cells of the lungs provides additional 
evidence that MC3R could modify lung function. Toether, these results suggest MC3R as 
a potential mediator of the inflammatory response and a possible therapeutic target in the 
treatment of CF. 
 In CF, airway inflammation is responsible for the chronic infections and leads to 
progressive loss of lung function and respiratory failure (102). Thus, reduction of the 
inflammatory burden in the airways can prevent irretrievable lung damage and therefore 
be beneficial to all CF patients, regardless of their CFTR genotypes. Because NF-κB 
plays a key role in regulating the expression of a large number of cytokines involved in 
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inflammation, the NF-κB signaling pathway is an ideal target for pharmacological 
intervention (226-229). Our initial analysis using CFTR as a reporter to measure NF-κB 
activity indicates that reduction of MC3R expression increases the level of CFTR by 3- to 
5-fold. This result highlights the potential of MC3R to regulate NF-κB activity.   
The NF-κB pathway in airway epithelial cells is believed to be critical in 
controlling lung inflammation through the release of several inflammatory mediators, 
such as IL-1β, IL-6, and IL-8 (230-232). There have been several studies that report the 
use of melanocortin peptides to inhibit the activation of NF-κB and repress the 
inflammatory signaling in various cell types, including inflammatory cells as well as 
airway epithelial cells (116,121,137-140). Given that MC3R has been previously 
implicated in inflammatory response, we sought to determine whether or not modulation 
of MC3R alters IL-8 levels in K562 cells. The cells were treated with PMA, a small 
molecule that activates protein kincase C (PKC), in order to stimulate an immune 
response. It is known that PKC activates IκB kinase, which degrades IκB and releases 
NF-κB to enter the nucleus in order to activate the expression of specific inflammatory 
genes, such as IL-8 (233-235). We found that upon reducing the expression of MC3R 
with siRNAs, IL-8 production was increased by 3- to 8-fold after PMA stimulation. On 
the other hand, activating MC3R with [D-Trp
8
]-γ-MSH led to a subtle decrease in IL-8 
level following stimulation with PMA. Our study confirms that increasing and decreasing 
signaling via MC3R alters the expression of pro-inflammatory genes, like IL-8. The 
evidence that MC3R may regulate the inflammatory response provides rationale for 
further investigation of the mechanisms underlying lung disease severity in hopes of 
designing synthetic analogs to treat inflammation.  
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MC3R expression is poorly characterized in human tissues. Here, we have 
demonstrated that MC3R is expressed in the airway epithelial cells of the lungs, which 
corroborates its potential role as a modifier of lung function. Several rationales have been 
considered to explain the differences seen in the level of MC3R in primary airway cells. 
The variable expression of MC3R may be attributed to MC3R genotype or heterogeneity 
of cell types obtained from lung transplants. The correlation between MC3R genotype 
and its protein expression warrants further investigation.  
There is increasing evidence that support the role of rare variants in both 
monogenic and complex diseases (236-239). Analysis of 151 sibling pairs with CF 
identified three rare variants in MC3R that associate with lung disease severity. The rare 
variants, however, did not explain the linkage signal on chr20q13.2. In fact, just one out 
of four sibling pairs carrying a rare variant contributed positively to the LOD score. This 
may be attributed to an insufficient sample size and the extreme rarity of individual 
variants. It has been reported that rare variants, despite potentially large effect size, can 
only be detected in large samples (240,241). Given that only 151 out of 484 sibling pairs 
in TSS cohort were sequenced, it is possible that additional rare variants that contribute to 
the previous linkage signal have not been identified.  
Significant association between three rare variants and lung function in the TSS 
cohort prompted us to search for protective and at-risk haplotypes. Though no haplotypes 
were associated with lung function, the small number of individuals harboring the rare 
haplotypes likely prevented potential significant associations to be uncovered. 
Furthermore, there have been other linkage studies in which the contribution of the at-risk 
haplotype to the linkage signal was not detected because non-carriers of the rare at-risk 
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haplotypes were the ones who were actually responsible for the majority of the linkage 
signal (15,242). Sequencing more sibling pairs may lead to the discovery of novel 
variants and haplotypes across MC3R, which can increase the power of association to 
detect the factors responsible for the linkage signal at chr20q13.2. 
To assess the deleterious effect of coding variants in MC3R, we applied three 
publicly available programs (SIFT, PolyPhen2, and Condel) to predict whether or not a 
nonsynonymous variant is likely to affect protein function. GERP was used in 
conjunction to determine the degree of evolutionary constraint on specific nucleotides 
through quantification of substitution deficits. All four coding variants had positive 
GERP scores, indicating that all sites were under evolutionary constraint. The in silico 
prediction algorithms concordantly reported the common variant, rs3827103 (p.V44I), as 
benign and the rare variant, g.54824368A>C (p.T157P), as damaging. Interestingly, the 
rare variant, rs61735259 (p.R220S), was scored as tolerated by SIFT, probably damaging 
by PolyPhen2, and deleterious by Condel, which demonstrates that the classification of 
mutations by these prediction tools is not always accurate. A possible explanation as to 
why various tools differ in their predictions on the functional effects of nonsynonymous 
variants could be that PolyPhen2, unlike SIFT, incorporates structural information in 
addition to sequence information. A benign prediction may need to be further 
investigated to verify that a given variant is truly tolerated (243). 
For this reason, we analyzed the MC3R transcript levels of three rare coding 
variants. MC3R mRNA level was lower in the individual carrying g.54824368A>C 
(p.T157P) variant compared to the sibling without the variant, which suggests that 
p.T157P is most likely deleterious. This conclusion is strongly supported by the 
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consistent prediction scores from three algorithms. On the other hand, MC3R mRNA 
level was higher in the individual with rs61735259 (p.R220S) variant compared to the 
sibling without the variant. Based on this result in combination with varying prediction 
scores of three algorithms, the pathogenic effect of p.R220S seems less likely. 
rs41274722 (p.I189I) is a synonymous change present in both siblings from one family. 
We expected the levels of MC3R mRNA to be similar in the siblings, but a large 
difference in MC3R mRNA implied that there may be variants in the promoter or trans-
acting factors that regulate the expression of this gene. At this time, there is not enough 
conclusive evidence that validates whether or not the rare variants in MC3R affect its 
function. Further studies are necessary to elucidate the functional impact at the protein 
level, if any, of these rare nonsynonymous variants. 
Despite considerable progress in CF therapy over recent decades, patients 
continue to experience longitudinal decline in lung function. The development of new 
therapies for CF requires identification of genetic loci that modify pulmonary disease 
severity as well as understanding of the mechanism at such loci. In this study, we 
evaluated the role of MC3R at chr20q13.2 as a potential modifier of lung function. Taken 
together, our study suggests that MC3R may modify CF lung disease severity by 
affecting IL-8 production through NF-κB signaling pathway. The development of a drug 
that selectively alters the expression of MC3R will be of great interest in modulating pro-






Materials & Methods 
 
Genomic DNA Extraction and Sanger Sequencing 
Peripheral blood was obtained from consented individuals and genomic DNA was 
extracted by combination of phenol/chloroform method. The gDNA was amplified using 
Taq DNA Polymerase (Invitrogen) and the following primers: 
Primers Direction Sequence (5’– 3’) 
MC3R-all  F CTT AAT CTC CCT GCA GAA TCC TC 
 R CAA ACG ACA AGT ACA ATC ATG G 
 
Following a 6-min denaturation at 95°C, 30 cycles of 95°C for 45 s, 58°C for 45 s and 
72°C for 2 min were performed, followed by a 10-min extension at 72°C. PCR products 
were visualized by agarose gel electrophoresis with ethidium bromide staining. The 




Lung disease severity was quantified using SaKNorm, a survival-adjusted average of CF-
specific percentiles for FEV1 using three years of FEV1 data and then transformed to the 
corresponding Z-score by normal transformation (112). Association of lung function with 
the number of SNP minor alleles was tested using linear regression. Nominal statistical 
significance was defined as P < 0.05. Study-wide significance was defined using 
Bonferroni correction for 7 tests (8 variants in total but 2 variants are in complete LD) 
(0.05/7 = 0.0071). Regression analyses were performed using Stata 11 (StataCorp, 




The variants discovered via Sanger sequencing were converted into .ped and .map 
formats.  The final .ped file contained 298 founders and 7 non-founders (related 
individuals) each with corresponding FEV1 coded as a quantitative trait. These files were 
used as input into both Haploview (244) and PLINK (245) software packages for both 
SNP and haplotype based association analysis.  An omnibus test of haplotypic association 
was conducted for all haplotypes present in the population (8 haplotypes; 7 degrees of 
freedom) via the PLINK --chap command (additional: --maf 0, --each-vs-others).  A SNP 
based association analysis was also conducted for all loci (8 variants) using the PLINK --
assoc command.  Comparable SNP and haplotype based association tests were performed 
using the Haploview GUI.  Additionally, Haploview was used to define blocks of linkage 
disequilibrium in both the present dataset and the HapMap project phase 3 dataset (CEU 
and TSI populations included). 
 
Pathogenicity prediction analysis 
SIFT uses the degree of conservation of amino acid resides in sequence alignments 
derived from closely related sequences in order to predict whether an amino acid 
substitution affects protein function (246). The amino acid substitution is predicted 
damaging is the score is <= 0.05, and tolerated if the score is > 0.05. PolyPhen2 predicts 
the possible impact of an amino acid substitution on the structure and function of a 
human protein by relying on sequence homology as well as structural information 
characterizing the substitution (247). A mutation is reported as benign, possibly 
damaging, probably damaging or unknown based on false positive rate thresholds. 
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Condel computes a weighted average of the deleteriousness scores from SIFT, PolyPhen2 
and MutationAssessor to assess the impact of non-synonymous variants on protein 
function (248). Results are given as neutral or deleterious. GERP identifies regions that 
exhibit nucleotide substitution deficits that reflect the intensity of past purifying selection 
and characterize evolutionary constraint (249). GERP scores range from -12.3 (least 
conserved) to 6.17 (most conserved). 
 
Cell Culture  
K562 cells and human transformed lymphocytes were maintained in RPMI 1640 Medium 
(Gibco) at 37°C in an atmosphere of 5% CO2. K562 cells were supplemented with 10% 
FBS (Cellgro) and 1% penicillin-streptomycin (Gibco). Human transformed lymphocytes 
were supplemented with 10% FBS (Cellgro). The lysates from primary human bronchial 
epithelial (HBE) cells were generous gifts from Dr. Joseph Pilewski (University of 
Pittsburgh). 
 
RNA isolation and reverse transcription PCR (RT-PCR) 
Total RNA was isolated from human transformed lymphocytes by using RNeasy Mini 
Kit (Qiagen) as described by manufacturer’s protocol. It was treated with DNA-free 
DNase (Ambion) to remove contaminating DNA as described by manufacturer’s 
protocol. The concentration of DNase-treated RNA was measured by NanoDrop™ 1000 
Spectrophotometer (Thermo Scientific). One microgram (1 µg) of DNase-treated RNA 
was reverse transcribed using iScript™ cDNA Synthesis Kit (Bio-Rad). All cDNA was 




qPCR was performed with SsoAdvanced
TM 
SYBR Green Supermix (Bio-Rad) using 
CFX96 Real-Time PCR Detection System (Bio-Rad). All samples were amplified in a 
minimum of triplicates. Amplifications were performed with a 3-min denaturation at 
95°C, followed by 40 cycles of 95°C for 10 s, 57°C for 10 s and 72°C for 15. Melt curves 
for each pair of primers were inspected to assess amplification specificity. The Cq values 
were normalized to two housekeeping genes: PPIA and TBP. Gene expression fold 
changes were calculated using the ΔΔCq method. The following primer pairs were used to 
detect mRNA expression of MC3R, PPIA and TBP: 
Primers Direction Sequence (5’– 3’) 
MC3R  F ACA GAA GGA AGA CAG CTG AGG A 
 R TGA TGA AGA CCT GCT CAC A 
PPIA F AGG TCC CAA AGA CAG CAG AA 
 R GAA GTC ACC ACC CTG ACA CA 
TBP  F AGA GTT CTG GGA TTG TAC CG 
 R TTC GTG GCT CTC TTA TCC TC 
 
Western blot  
Cells were lysed in buffer containing 1 M Tris (pH 7.4), 4 M NaCl, 0.5 M EDTA, 1% 
NP-40, and protease inhibitor cocktail. The brain tissue was homogenized and sonicated 
in RIPA buffer with protease inhibitor cocktail. Samples were denatured in Laemmli 
sample buffer (Bio-Rad) at 42°C for 20 min for CFTR proteins or in NuPAGE LDS 
sample buffer (Invitrogen) at 100°C for 5 min for all other proteins. Proteins were 
subjected to electrophoresis in 7.5% SDS-PAGE gels (Bio-Rad) and transferred to PVDF 
membranes (Bio-Rad). The membranes were blocked with 5% NFDM for an hour and 
incubated overnight at 4°C with primary antibodies diluted appropriately in 0.1% PBST: 
MC3R (Abcam ab93368) at 1:5,000; β-actin (Sigma) at 1:15,000; GAPDH (Sigma) at 
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1:15,000; β-tubulin (Sigma) at 1:15,000; CFTR (mAb596 and mAb570 generated by Dr. 
Riordan’s group at UNC Chapel Hill) at 1:15,000. Then they were washed several times 
with 0.1% PBST for an hour and incubated for 1 h at room temperature with secondary 
antibodies diluted 1:50,000. The signal was detected by enhanced chemiluminescence 
Prime Western Blotting Detection Reagents (GE Healthcare). ImageJ software was used 
to quantify the bands. 
 
Immunohistochemistry  
After the tissues were fixed in 4% formalin for 24 hours and embedded in paraffin, 4 μm 
sections were cut and mounted on plus glass slides. The sections were deparaffinized in 
xylene and then hydrated through exposure with graded alcohols (100%, 95%, 70%, 
50%, water, PBS). The slides were immersed in either antigen retrieval solution (Dako, 
citrate buffer, pH 6.0) and heated for 20 min or Proteinase K solution (Fisher) at 20 μg/ml 
in 37°C humidified chamber for 20 min. After cooling to room temperature, the slides 
were incubated with 0.03% hydrogen peroxide for 5 min to quench endogenous 
peroxidase activity (Dako). Subsequently, they were incubated with blocking solution 
(Dako) for 30 min to block non-specific binding. They were incubated with appropriately 
diluted primary antibodies (Dako; Abcam ab93368 at 1:1000; LS Bio LS-A452 at 1:100-
1:500) overnight at 4°C. As negative controls, the primary antibodies were replaced with 
immunoglobulin fraction of serum from non-immunized rabbit (Dako) or with antibodies 
that have been incubated with the immunizing peptide at 5-fold excess (Abcam). After 
washing the primary antibodies with TBST, peroxidase labeled polymer conjugated to 
goat anti-rabbit immunoglobulins were added for 30 min. For signal detection, the slides 
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were incubated with AEC-chromogen solution (Dako) for 15 min, counterstained with 
hematoxylin (Dako) and mounted in mounting media (Dako). Photomicrographs were 
taken with Nikon Eclipse 50i. 
 
Transfection  
K562 cells were transfected with siRNAs using Lipofectamine RNAiMAX (Invitrogen) 
according to the manufacturer's instructions. In certain experiments, K562 cells were 
subsequently transfected with 1.5 µg of CFTR plasmids using Lipofectamine 2000 
(Invitrogen) 2 days after the initial siRNA transfection. Cells were harvest 4 days after 
the initial transfection. Two negative control siRNAs that have no homology to any 
mammalian gene were used as controls: AllStars Negative Control siRNA (Qiagen; 
“Neg. siRNA #1”) and Silencer Select Negative Control siRNA (Ambion; “Neg. siRNA 
#2”). ON-TARGETplus MC3R siRNA SMARTpool, a mixture of 4 siRNAs provided as 
a single reagent, was used to target MC3R (Thermo Scientific). The sequences of the 
MC3R siRNAs are described below: 
ON-TARGETplus SMARTpool siRNA J-005659-06, MC3R  CCGACAUGCUGGUAAGUGU 
ON-TARGETplus SMARTpool siRNA J-005659-07, MC3R  GUGAGCAGGUCUUCAUCAA 
ON-TARGETplus SMARTpool siRNA J-005659-08, MC3R  GGAGGGAGAUUUUGUCUUU 
ON-TARGETplus SMARTpool siRNA J-005659-09, MC3R  GAAUUGCGCAACACCUUUA 
 
ELISA 
To examine the expression of IL-8, K562 cells were stimulated with indicated 
concentration of PMA for 6 hours. In some experiments, K562 cells were incubated with 
indicated concentration of [D-Trp
8
]-γ-MSH for 12 hours prior to PMA stimulation. IL-8 
secretion was measured using a human IL-8 ELISA kit (Invitrogen) according to the 
manufacturer’s protocol. Briefly, the supernatants were harvested and added to IL-8 
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antibody-coated 96-well plates. After the addition of biotinylated antibody and 
streptavidin-peroxidase, tetramethylbenzidin was used as a stabilized chromogen. The 
absorbance of each well was read at 450 nm using a microplate reader. IL-8 

















































CF is a Mendelian autosomal recessive genetic disorder caused by loss-of-
function mutations in CFTR. Airway inflammation and chronic infection lead to 
progressive destruction of the lungs, making lung disease the major cause of morbidity 
and mortality in CF. Since the discovery of CFTR as the disease-causing gene for CF, 
considerable progress has been made in improving nutrition, adequate growth and lung 
function among patients with CF. Nearly half of all people with CF are now ages 18 and 
older. The steady increase in the median predicted age of survival in the last 25 years 
signifies the significant advances that have been made in the development of new drugs 
and therapies.  
Despite its Mendelian pattern of inheritance, CF demonstrates considerable 
variability in disease severity and clinical presentation, independent of CFTR genotype. 
Therefore, it is critical to determine the magnitudes of non-CFTR genetic variation and 
environmental effects that contribute to the variability of the phenotypes. A high 
correlation for genetic modifier contribution to CF disease severity using twin-based 
assessment suggests that genes other than CFTR contribute to the disease manifestation. 
The heritability estimate of lung function based on FEV1 ranged from 0.54 to 1, further 
confirming that genetic modifiers play an integral role in lung disease severity. The lack 
of a cure for this life-limiting disease fuels the search for modifier genes, which will 
serve as new targets for therapeutic intervention.  
Kalydeco
TM
, the first mutation-targeted drug to treat the underlying cause of CF, 
potentiates the open-channel probability of the defective CFTR gate. It was initially 
approved for those who have the G551D mutation. On Feb. 21, 2014, FDA approved 
expanded use of this drug for eight additional mutations: G1244E, G1349D, G178R, 
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G551S, S1251N, S1255P, S549N, or S549R. Substantial improvements in lung function 
and nutritional status have been observed in patients on Kalydeco
TM
 (68). Nonetheless, 
Kalydeco
TM
 has not shown to reduce or prevent inflammation that frequently results in 
chronic infection. The lack of change in inflammatory status may indicate that 
improvement of CFTR function does not reverse the imbalance in inflammation triggered 
by the consequence of CFTR dysfunction. Steroids have been used in the past to 
counteract the inflammatory process, but adverse effects have limited the use of such 
drugs (250,251). Identifying modifiers of the inflammatory process could provide new 
therapeutic targets to complement CFTR-directed therapy.  
The work presented in this thesis has contributed to the field of molecular 
biology. In Chapter 2, we report molecular and cellular characterization of human MC3R 
gene. Prior to our work, MC3R was predicted to be a single-exon gene with uncertain 
translation start site. Our study was the first to unveil that MC3R is a two-exon gene that 
requires its 5’ UTR to begin translation at the second in-frame ATG and apically localize 
within polarized cells. Our identification of the transcription start site of MC3R defined 
the location of the promoter and other regulatory element binding sites that control the 
gene expression. Those who are interested in understanding the mechanism behind MC3R 
gene regulation can now search for variants and haplotypes in the correct promoter region 
and design their assays accordingly. The understanding of the mechanism that governs 
MC3R translation initiation enables accurate interpretation of the functional 
consequences of DNA variants that confer risk for obesity and other phenotypes. In 
addition, we provide evidence for likely interaction between MC3R and MRAP2. Given 
that our data indicates that MRAP2 may have unknown roles besides being an accessory 
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factor for MC2R, determining if and how MRAP2 modulates the function of MC3R 
warrants further investigation. Taken together, our study demonstrates that a previously 
unannotated 5’ exon directs translation of MC3R that localizes to the apical membranes 
of polarized cells and possibly interacts with (or is assisted by) MRAP2.  
Moreover, this thesis makes several important contributions to the field of genetic 
modifiers in CF. In Chapter 3, we describe common and rare variants in MC3R identified 
through Sanger sequencing. We present evidence that three of the rare MC3R variants are 
associated with lung disease severity in CF. The benefit of sequencing is that this 
approach does not rely on strong LD with genotyped markers to determine causative 
alleles. In fact, array-based genotyping technologies as well as imputation methods 
cannot be used to detect rare variants that associate with many diseases. Therefore, our 
study design, while laborious, is well-suited to detect rare variants that may contribute to 
a trait. The identification of common and rare variants allowed us to construct the 
haplotypes across the MC3R locus. While we were unable to associate any of the 
haplotypes with lung function, our work on the derivation of the rare haplotypes from the 
major haplotypes provides the foundation for future haplotype analysis. Furthermore, our 
research reveals the role of MC3R in the regulation of the pro-inflammatory signaling. 
Since ameliorating airway inflammation can improve overall lung function in all patients 
with CF, it will be crucial to understand how MC3R alters the inflammatory response in 
order to design appropriate small molecules that target MC3R.  
Rare variants play an important role in the etiology of complex traits and account 
for missing heritability unexplained by common variants (239,252). The coding variants 
are especially useful in understanding the function of a gene that is linked to a specific 
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phenotype. While rare variants tend to have large effect size, natural selection prevents 
them from becoming common if their impact is deleterious. Hence, analysis of individual 
rare variants requires very large samples (253), which makes Sanger sequencing an 
impractical choice. Besides Sanger sequencing, there are other ways to identify rare 
variants: deep- or low-coverage whole genome sequencing and targeted sequencing. Due 
to cost, deep-coverage whole genome sequencing can only be applied to limited numbers 
of samples. The benefit of this approach is that it provides the most complete catalog of 
variation. On the other hand, low-coverage whole genome sequencing can be performed 
on more samples, but the limitation of this approach is that not all rare variations will be 
ascertained with confidence. While targeted sequencing serves as a compromise between 
deep- vs. low-coverage whole genome sequencing, it requires a priori knowledge of what 
region of the genome to target. One of the our future studies includes targeted sequencing 
of MC3R as well as other modifier genes in additional samples in order to detect rare 
variants and establish rare haplotypes that can explain the linkage signal at chr20q13.2. 
As an alternative to testing rare variants individually, efforts have been devoted to 
developing statistical methods to test associations between combinations of rare variants 
and complex traits. Because rare variant tests independently do not have enough power to 
detect its effects, they have been collapsed to test cumulative effects of rare variants in a 
so-called burden test. Aggregating rare variants substantially increases power, which 
depends on frequency and effect size. There are different examples of the burden tests: 
cohort allelic sum test (254), combined multivariate and collapsing method (255), and 
non-parametric weighted sum test (256). Each test makes different assumptions about the 
rare variant effects and has its own limitations. Once more rare variants are detected 
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through targeted sequencing of additional CF patients, we are interested in performing an 
appropriate burden test to find the association between rare variants in a region (i.e. 
MC3R) and lung disease severity. 
The research presented in this thesis has advanced our understanding of the 
mechanism by which MC3R may regulate pro-inflammatory signaling pathway in CF. 
More work remains to be done to determine how rare variants affect MC3R function and 
alter the inflammatory response. Such in vitro functional studies will require the 
utilization of transformed lymphocytes or primary cells from the patients themselves or a 
creation of an appropriate cell line that contains the rare variants. Once we determine the 
most suitable system for studying the proposed mechanism, we hope to gain novel 
insights in the role of MC3R in inflammation.  
Collectively, our study has uncovered a novel target, MC3R, that may be 
amenable to therapeutic interventions in patients with CF. Although the contribution of 
each genetic modifier to the overall variability in disease presentation is most likely 
small, identification of modifiers promotes alternative or additional ways to treat CF. If 
patients can increase the functional activity of their mutant CFTR protein through a drug 
like Kalydeco
TM
 while managing their inflammation with a different drug that targets a 
modifier gene, they may experience an improved quality of life and increased longevity. 
If a modifier of CF lung disease is implicated in another disease in which therapies 
already exist, CF patients may promptly benefit from existing treatments. Because 
genetic modifiers operate in the context of the genome in response to the environmental 
exposure, it may be difficult to tease out the complex relationship. Nonetheless, 
identification of true modifiers and their respective pathways signify potential new 
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targets for therapies against CF lung disease. Since airway inflammation impairs all CF 
patients’ lung function regardless of CFTR genotype, development of a drug that can 
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EDUCATION 
Ph.D. in Human Genetics, Johns Hopkins School of Medicine Expected May 2014 
 
M. Ed., Teacher Education Program, University of California, Los Angeles (UCLA) 2008 
Preliminary Single Subject (Biology) Credential with Cross-cultural, Language and Academic 
Development Emphasis 
 
B. S., Molecular, Cell, and Developmental Biology, UCLA 2007 
Minor in Asian Languages and Cultures (Korean) 
Phi Beta Kappa, magna cum laude with highest departmental honors 
 
RESEARCH 
Institute of Genetic Medicine, Johns Hopkins School of Medicine 2010-current 
Advisor: Dr. Garry Cutting, Department of Pediatrics 
Molecular characterization of MC3R and evaluation of its potential role as a modifier of lung 
function in cystic fibrosis 
 
Department of Human Genetics, UCLA Summer 2008 
Advisor: Dr. Karen Reue, Department of Human Genetics 
Examination of the transcriptional regulation of Diet1 gene, which is responsible for 
abnormalities in lipid and glucose metabolism in mice, and aimed to isolate the mutation that 
confers resistance to atherosclerosis 
 
School of Education and Information Studies, UCLA 2007-2008 
Advisor: Dr. Imelda Nava-Landeros, Teacher Education Program 
Investigation of ways to build a college-bound classroom culture and to transform my classroom 
into the space of empowerment where students could develop a sense of responsibility for their 
success  
 
Department of Molecular, Cell & Dev. Biology, UCLA 2005-2007 
Advisor: Dr. L. Jeanne Perry, Director of UCLA Protein Expression Technology Center 
Analysis of the structures and functions of M. tuberculosis proteins, Rv3878 and Rv3879c, for 




Department of Biology, Johns Hopkins University (Baltimore, MD) Winter 2014 
Instructor – Ethical Issues in Human Genetics (26 undergraduate students) 
 Successfully proposed a new undergraduate course called Ethical Issues in Human Genetics 
for Johns Hopkins Winter Intersession Programs 
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 Created a curriculum that explored various ethical issues in human genetics, such as pre-
implantation genetic diagnosis, newborn screening, rare disease research, genetic 
discrimination, and gene therapy 
 
Department of Biological Sciences, Towson University (Towson, MD) 2012-2013 
Adjunct Faculty 
 Fall 2013: Biology 190, Introductory Biology for the Health Professions (48 undergraduate 
students) 
 Fall 2012: Biology 120, Principles of Biology (44 students); Biology 120 Lab (24 students) 
 Spring 2012: Biology 115, Biology - The Science of Life  (42 students) 
 
Molecular Biology and Genetics, Johns Hopkins School of Medicine (Baltimore, MD)  
Teaching Assistant – Fundamental of Genetics (80 graduate students)                             Fall 2013 
 Worked with Dr. Jeremy Nathans to design a 100-point problem set that covered human 
genetics and population genetics portion of the course  
 
Institute of Genetic Medicine, Johns Hopkins School of Medicine (Baltimore, MD)  
Teaching Assistant – Evolution of the Concept of a Gene (12 graduate students)              Fall 2011 
 Organized meetings with the first-year graduate students prior to their presentations 
 Maintained a Blackboard course website  
 
Los Altos High School (Hacienda Heights, CA) 2008-2009 
Biology Teacher 
 Taught 3 regular and 2 special education biology classes  
 Created a class website on Blackboard to facilitate communication with students and parents 
 Served as an advisor for Science Olympiad in the “Picture This” category (placed 2nd in state) 
 
Elite Educational Institute (Fullerton, CA) 2008-2009 
SAT Math Instructor 
 Prepared over 100 students for the math section of the SAT Reasoning Test 
 
Locke High School (Los Angeles, CA) 2007-2008 
Biology Teacher 
 Taught 2 honors, 2 regular and 1 sheltered (for English Language Learners) biology classes 
in a Program Improvement school in the Watts community  
 Organized and facilitated a professional development seminar for the biology department 
 Provided outside educational opportunities for the students  
 
University High School (Los Angeles, CA) 2005-2007 
Advancement Via Individual Determination (AVID) Program Intern 




Mentoring Undergraduates in Interdisciplinary Research (Baltimore, MD) 2012-2013 




 Designed an 1-year research project in which she characterized a potential modifier gene by 
identifying variants, determining its molecular mass, and confirming its expression in lung 
tissues 
 Taught basic laboratory skills and molecular biology techniques, such as PCR, site-directed 
mutagenesis, gel electrophoresis, transformation, DNA extraction, Western blot, and Sanger 
sequencing 
 Gave a lecture on Genomics and Its Impact on Science and Society: The Human Genome 
Project and Beyond to all undergraduate students participating in this program 
 
Human Genetics Predoctoral Training Program (Baltimore, MD) Fall 2012 
Mentor Scientist for Kaitlin Victor, a first-year human genetics rotation student  
 Supervised a graduate student who studied methylation pattern in the promoter region of 
GNAS gene in monozygotic twins with cystic fibrosis 
 
Baltimore Excellence in STEM Teaching Project (Baltimore, MD) Summer 2011 
Mentor Scientist for Jon Rosenblum, a high school biology teacher  
 Defined a 6-week research project in which he sequenced the exons of CSE1L, a gene that was 
discovered to be a negative regulator of CFTR-dependent fluid secretion 
 Provided technical support and hands-on training for the teacher intern 
 Helped develop an engaging and relevant genetics curriculum that contained lessons from the 
summer research 
 
MANUSCRIPTS IN PREPARATION OR UNDER REVIEW 
Sharma N, Sosnay P, Ramalho A, Douville C, Franca A, Gottschalk L, Park J, Siklosi K, Amaral 
M, Karchin R, Cutting GR. (2014) Accuracy of algorithms in predicting the consequences of 
splice site variants. [manuscript under review] 
 
Park J, Sharma N, Cutting GR. (2014) Molecular and cellular characterization of the human 
melanocortin-3-receptor (MC3R). [manuscript under review] 
 
Park J, Sharma N, Vecchio-Pagán B, Franca A, Lee M, Gottschalk L, Pilewski J, Belchis D, 
Blackman S, Cutting GR. (2014). Melanocortin-3-receptor (MC3R) modifies lung disease severity 
in individuals with cystic fibrosis. [manuscript in preparation] 
 
PROFESSIONAL PRESENTATIONS 
Park J, Rose A, Ingram M, Vieira N. Beyond Mendel: Complexities of Simple Mendelian 
Disorders. 64
th
 Annual Meeting of the American Society of Human Genetics; 2014 Oct. 18-22 
(expected); San Diego, CA. [invited session] 
 
Park J, Pilewski J, Belchis D, Blackman S, Cutting GR. MC3R modifies CF lung disease by 
increasing the level of CFTR. 63
rd
 Annual Meeting of the American Society of Human Genetics; 
2013 Oct. 22-26; Boston, MA. [platform] 
 
Park J, Vecchio-Pagán B, Cuppens H, Cutting GR. SNP genotyping is a valuable tool for 
assessing the quality of next generation sequencing data. 62
nd
 Annual Meeting of the American 




Park J, Sharma N, Cutting GR. Evaluation of the melanocortin-3-receptor as a potential 
modifier of CF lung disease. 26
th
 Annual North American Cystic Fibrosis Conference; 2012 Oct. 
11-13; Orlando, FL. [poster] 
 
Kapa L, Sharma N, Park J, Cutting GR. Creation of a CFBE41o- cell line with a single 
integration site for the expression of rare CFTR mutants. 26
th
 Annual North American Cystic 
Fibrosis Conference; 2012 Oct. 11-13; Orlando, FL. [poster] 
 
Sharma N, Kapa L, Park J, Sosnay P, Cutting GR. Overexpression of NHERF1 promotes 
recycling of a naturally occurring CFTR C terminus truncation mutant. 25
th
 Annual North 
American Cystic Fibrosis Conference; 2011 Nov. 3-5; Anaheim, CA. [poster] 
 
Park J. Building a college-bound classroom culture by encouraging students to develop 
responsibility for their success. UCLA Teacher Education Program Secondary Resident Inquiry 
Poster Session; 2008 Jun. 4; Los Angeles, CA. [poster] 
 
Park J, Eng A, Chiang J, Chan S, Pham M, Shin A, Elbogen J, Perry J. Characterization of RD1 
Proteins, Rv3878 and RV3879c, in Mycobacterium tuberculosis. UCLA Annual Science Poster 
Day; 2006 May 24; Los Angeles, CA. [poster] 
 
ACTIVITIES AND SERVICE 
American Society of Human Genetics (Bethesda, MD) 2014-current 
Information & Education Committee Member  
 Carry out activities concerned with information relevant to human genetics as it relates to 
the education of students in general, the training of professionals in human genetics, and the 
awareness of human genetics by the general public 
 
Johns Hopkins Diversity in Graduate Education Sub-committee (Baltimore, MD) 2012-2013 
Graduate Student Member  
 Wrote a proposal for a $200,000 grant over two years to increase and support diversity in 
graduate education at Johns Hopkins University School of Medicine  
 Planned to create a bridge program for admitted graduate students to increase readiness for 
transitioning from a student to a professional, help them manage research time, provide 
networking opportunities, and enhance the feeling of community 
 
Towson Teaching Fellowship Program (Towson, MD) 2012 
Selection Committee Member 
 Reviewed 21 applications for Teaching Fellows at Towson University 
 
Towson Teaching Fellowship Program (Towson, MD) 2011-2012 
Teaching Fellow 
 Completed 3-semester teaching fellowship that is designed to prepare future university 
faculty to use research based pedagogical practices in college classrooms 
 Attended pedagogy seminars focused on teaching a non-majors course and observed current 
instructors in the first semester of the program 
 Was the instructor of record of an introductory biology course (Biology 115) and an adjunct 









Incentive Mentoring Program (Baltimore, MD) 2011-2012 / 2010-11 / 2009-10 
Communications Director / Head of Household / Volunteer  
 Diagnosed issues within the organization and provide a formal mechanism for addressing 
concerns 
 Conducted organization-wide surveys and led a leadership training for new Heads of 
Household 
 Managed a group of 10 volunteers to provide support for Kayla, an African American girl 
who had failed two years of school and lived with an unemployed father and a sick mother, 
by tutoring her twice a week, serving as a liaison to teachers, planning college visits, and 
providing transportation in times of need 
 
UCLA Recreation (Los Angeles, CA) 2005-2008 
Fitness Instructor     
 Taught over 100 group exercise classes, such as Total Body Challenge, Super Step Circuit, 
Ultimate Upper Body, Extreme Step, Hip Hop Sets-N-Reps, etc. 
 Earned Group Fitness Certification through American Council on Exercise (ACE) 
 
AWARDS AND HONORS 
Los Altos High School Teacher of the Month  October 2008 
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